A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Phase: PHASE2
Conditions: Migraine
Sponsor: Pfizer

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 1 of 91
DRUG:
BHV-3000 (rimegepant)
STUDY NUMBER(S):
BHV3000-305
PROTOCOL(S) TITLE:
BHV3000-305: A Phase 2/3, Randomized, Double-
blind, Placebo-controlled Study to Evaluate the 
Efficacy and Safety of Rimegepant in Migraine 
Prevention
IND NUMBER:
109886
SPONSOR:
Biohaven Pharmaceuticals, Inc.
ORIGINAL PROTOCOL 
DATE:
27 July 2018
VERSION NUMBER:
V09
VERSION DATE:
25 August 2020
NCT Number: NCT03732638

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 2 of 91
CLINICAL PROTOCOL APPROVAL FORM
Protocol Title: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the 
Efficacy and Safety of Rimegepant in Migraine Prevention
Study No: BHV3000-305
Original Protocol Date: 27 July 2018
Protocol Version No: V09 (Amendment 08)
Protocol Version Date: 25 August 2020
This study protocol was subject to critical review and has been approved by the 
appropriate protocol review committee of the sponsor.  The information contained in this 
protocol is consistent with:

The current risk-benefit evaluation of the investigational product.

The moral, ethical and scientific principles governing clinical research as set out in 
the Declaration of Helsinki, and principles of GCP as described in 21 CFR parts 50, 
54, 56 and 312 and according to applicable local requirements.
The Investigator will be supplied with details of any significant or new findings, 
including adverse events, relating to treatment with the investigational product.

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 3 of 91
SUMMARY OF CHANGES
Change
Section(s) Affected
Summary (changes are noted in bold)
Allow for Study 
Medication to be 
shipped to a subject 
due to COVID-19 
Pandemic
Section 4.3 / Table 2 / Footnote 6
Original Wording:
6 Subjects should finish a bottle of study 
medication before starting a new bottle.  
Study drug will be dispensed at monthly 
(every 4 weeks) study visits, as needed.  
Unscheduled visits to dispense study 
medication may be scheduled as needed.  
Updated Wording:
6 Subjects should finish a bottle of study 
medication before starting a new bottle.  
Study drug will be dispensed at monthly 
(every 4 weeks) study visits, as needed.  
Unscheduled visits to dispense study 
medication may be scheduled as needed.  Due 
to the COVID-19 Pandemic, study 
medication may be shipped to a subject, 
with up to an 8-week supply.  Proper 
documentation must be maintained in the 
subject’s source records including shipping 
vendor, tracking number, confirmation of 
receipt by subject, and all other relevant 
information.
Rationale:
This change was included to allow flexibility 
in cases where the COVID-19 Pandemic 
impacts study visits.
Allow for Remote 
Visits (ex: Telephone, 
Telemedicine) due to 
COVID-19 Pandemic
Section 4.3 / Table 2 / Footnote 
10
Original Wording:
10 While on-study, all visit windows are used 
for scheduling purposes and all efforts should 
be made to return subjects to the 28-day 
schedule if scheduling changes are made at 
any previous visit(s).  
Updated Wording:
10 While on-study, all visit windows are used 
for scheduling purposes and all efforts should 
be made to return subjects to the 28-day 
schedule if scheduling changes are made at 
any previous visit(s).  Due to the COVID-19 
Pandemic, visits may be conducted 
remotely (ex: telephone, telemedicine) and 
must be documented within the source 
records as being conducted remotely.  All 
procedures not able to be completed due to 
a visit being conducted remotely must be 

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 4 of 91
reported as a protocol deviation and can be 
performed at the next visit, where 
appropriate to do so based on subject 
presentation.  In cases where a Week 64 / 
End of Treatment (EOT) visit occurs
remotely in order to be completed during 
the protocol required window and due to 
the COVID-19 Pandemic, the subject 
should return to the site within the 8 Week 
Follow-up Safety Visit timeframe (8 weeks 
from last dose, -2 to +14 days), to complete 
all procedures that weren’t able to be 
completed remotely.  Procedures completed 
at the Week 64 / EOT Remote Visit do not 
need to be repeated.
Rationale:
This change was included to allow flexibility 
in cases where the COVID-19 Pandemic 
impacts study visits.
Allow for Remote 
Visits (ex: Telephone, 
Telemedicine) due to 
COVID-19 Pandemic
Section 4.3.3 / Open-label 
Extension Phase (52 weeks)
New wording: 
Due to the COVID-19 Pandemic, visits may 
be conducted remotely (ex: telephone, 
telemedicine) and must be documented 
within the source records as being 
conducted remotely.  All procedures not 
able to be completed due to a visit being 
conducted remotely must be reported as a 
protocol deviation and can be performed at 
the next visit, where appropriate to do so 
based on subject presentation.  
Allow for flexibility 
and to ensure 
completion of the 
Week 64 visit due to 
visits being impacted 
by the COVID-19 
Pandemic
Section 4.3.4 / End of Treatment 
(Week 64) 
Original Wording:
Subjects will return to the study at the end of 
Week 64 (±3 days), or at end of treatment for 
early discontinuations, for review of the 
electronic diary, assessment of medication 
compliance, assessment of tolerability and 
safety (including vital signs, laboratory tests,  
and  electrocardiography) (Table 2).  Subjects 
will return the unused study medication and 
electronic subject diary to the study site. 
Subjects who do not complete the Double-
blind, Treatment Phase and/or do not enter or 
complete the Open-label, Extension Phase 
should complete the End of Treatment Visit, 
2-Week Follow up Safety Visit and 8-Week 
Follow up Safety Visit.
Updated Wording:

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 5 of 91
Subjects will return to the study at the end of 
Week 64 (±3 days), or at end of treatment for 
early discontinuations, for review of the 
electronic diary, assessment of medication 
compliance, assessment of tolerability and 
safety (including vital signs, laboratory tests,  
and  electrocardiography) (Table 2).  In cases 
where a Week 64 / End of Treatment 
(EOT) visit occurs remotely in order to be 
completed during the protocol required 
window and due to the COVID-19 
Pandemic, the subject should return to the 
site within the 8 Week Follow-up Safety 
Visit timeframe (8 weeks from last dose, -2 
to +14 days), to complete all procedures 
that weren’t able to be completed remotely.  
Procedures completed at the Week 64 / 
EOT Remote Visit do not need to be 
repeated.  Subjects must return the unused 
study medication and electronic subject diary 
to the study site. Subjects who do not 
complete the Double-blind, Treatment Phase 
and/or do not enter or complete the Open-
label, Extension Phase should complete the 
End of Treatment Visit, 2-Week Follow up 
Safety Visit and 8-Week Follow up Safety 
Visit.
Rationale:
This change was included to allow flexibility 
in cases where the COVID-19 Pandemic 
impacts study visits and reinforces 
requirement for unused study medication to be 
returned.
Allow for flexibility 
and to ensure 
completion of the 8-
Week Follow-up 
Safety Labs due to 
visits being impacted 
by the COVID-19 
Pandemic
Synopsis / Study Schematic
Section 4.2 / Figure 1 / Study 
Schematic
Section 4.3 / Table 2 / Header 
titled: 8-Week Follow-up Safety 
Visit (8 weeks ±2 days after EOT 
visit)
Section 4.3.6 / 8-Week Follow up 
Safety Visit
Original Wording:
8-Week Follow-up Safety Visit (8 weeks ±2 
days after EOT visit)
Updated Wording:
8-Week Follow-up Safety Visit (8 weeks (-2 
to +14 days) after EOT visit)
Rationale:
This change was included to allow flexibility 
to the final safety follow-up visit in cases 
where the COVID-19 Pandemic impacts this 
visit, requiring it to be conducted remotely at 
the 8-week follow-up timepoint.  Subjects 
should be contacted at the 8-week follow-up 
timepoint to collect safety information, per 
protocol, and then should return to the office 

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 6 of 91
within 2 weeks to have the laboratory tests 
completed.  Tests may also be performed 
locally, if needed, in cases where a study site 
is not open to laboratory test collection.
Corrected 
Typographical Errors 
and Made Wording
Clarifications
Protocol Version 8
Corrected typographical errors and clarified 
wording throughout the document

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 7 of 91
BHV3000-305
BHV3000-305: A Phase 2/3, Randomized, Double-blind, 
Placebo-controlled Study to Evaluate the Efficacy and Safety 
of Rimegepant in Migraine Prevention
CONFIDENTIALITY AND INVESTIGATOR STATEMENT
The information contained in this protocol and all other information relevant to
BHV-3000 (rimegepant) are the confidential and proprietary information of Biohaven 
Pharmaceuticals, Inc., and except as may be required by federal, state or local laws or 
regulation, may not be disclosed to others without prior written permission of Biohaven 
Pharmaceuticals, Inc.
I have read the protocol, including all appendices, and I agree that it contains all of the 
necessary information for me and my staff to conduct this study as described. I will 
conduct this study as outlined herein, in accordance with the regulations stated in the 
Federal Code of Regulations for Good Clinical Practices and International Conference on 
Harmonization guidelines, and will make a reasonable effort to complete the study within 
the time designated.
I will provide all study personnel under my supervision copies of the protocol and any 
amendments, and access to all information provided by Biohaven Pharmaceuticals, Inc. 
or specified designees. I will discuss the material with them to ensure that they are fully 
informed about BHV-3000 and the study.
_________________________________
_____________________________
Principal Investigator Name (printed)
Signature
___________ ___________
Date
Site Number

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 8 of 91
STUDY SUMMARY (SYNOPSIS)
Title: 
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to
Evaluate the Efficacy and Safety of Rimegepant in Migraine 
Prevention
Rationale: 
Rimegepant is being developed for the treatment of migraine. 
Effectiveness for the acute treatment of migraine was initially 
demonstrated in a Phase 2b double-blind, randomized, placebo-
controlled, dose-ranging study where rimegepant at 75 mg showed 
efficacy on all four traditional endpoints: pain, nausea, photophobia 
and phonophobia.1 Efficacy was confirmed in two pivotal Phase 3 
trials using the current registrational co-primary endpoints of Pain 
Freedom and Freedom from Most Bothersome Symptom at 2 hours 
after dosing.
This study is being conducted to evaluate the efficacy, safety, and 
tolerability of rimegepant for the prevention of migraine.
Target 
Population:
The study will recruit male and female subjects, 18 years of age or 
older with at least a one-year history of migraine (with or without aura) 
consistent with a diagnosis according to the International Classification 
of Headache Disorders, 3rd edition.2 Per their own report, subjects
must have migraine onset prior to age 50, migraine attacks that last 
4-72 hours (if not treated) and have had, 4-18 migraine attacks of 
moderate to severe intensity per 4 weeks period within the 12 weeks
prior to the screening visit. After a 28-day observation period of 
standard of care, up to approximately 800 eligible subjects will be 
randomized to receive rimegepant or placebo, with dosing on an every 
other day (EOD) dosing schedule.  At the completion of the 12-week 
double-blind, treatment phase, subjects will be evaluated for entry into 
the 52-week open label, extension phase if laboratory test results meet
protocol entry criteria (Table 2).
Number of 
Subjects:
Approximately 1500 subjects will be screened to randomize up to 
approximately 800 subjects to rimegepant or placebo.  It is estimated 
that approximately 675 subjects will be entered into the open-label 
extension phase.   

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 9 of 91
Objectives: 
Primary Objective: 

To compare the efficacy of rimegepant to placebo as a preventive 
treatment for migraine, as measured by the reduction from baseline in 
the mean number of migraine days per month in the last 4 weeks of the 
double-blind treatment phase. (A month is defined as 4 weeks for the 
purpose of this protocol.)
Secondary Objectives:

To compare the efficacy of rimegepant to placebo on the 
proportion of subjects that have at least a 50% reduction from baseline 
in the mean number of moderate to severe migraine days per month in 
the last 4 weeks of the double-blind treatment phase.

To compare the efficacy of rimegepant to placebo on the reduction 
from baseline in the mean number of migraine days per month over the 
entire course of the double-blind treatment phase.

To compare the frequency of use of rescue medications between 
rimegepant and placebo in the last 4 weeks of the double-blind 
treatment phase.

To compare the efficacy of rimegepant to placebo on the reduction 
from baseline in the mean number of migraine days per month in the 
first 4 weeks of the double-blind treatment phase.

To evaluate the safety and tolerability of rimegepant.

To evaluate the frequency of ALT or AST > 3x ULN with 
concurrent elevations in bilirubin > 2x ULN in subjects treated with 
rimegepant.

To evaluate the frequency of hepatic-related adverse events (AEs) 
and the frequency of hepatic-related treatment discontinuations in 
subjects treated with rimegepant. 

To compare the change from baseline in the Migraine-Specific 
Quality-of-Life Questionnaire v 2.1 (MSQ) role function - restrictive 
domain score at Week 12 of the double-blind treatment phase between 
rimegepant and placebo.

To compare the change from baseline in the Migraine Disability 
Assessment (MIDAS) total score at Week 12 of the double-blind 
treatment phase between rimegepant and placebo.

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 10 of 91

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 11 of 91
Study Design: This is a multicenter, randomized, double-blind, placebo-controlled 
study to assess the efficacy and safety of rimegepant in migraine 
prevention with an open-label extension phase.  
The Screening phase includes a screening visit and a 28-day 
Observation Period. For subjects to be eligible for the study, they must 
report having had 4-18 migraine attacks of moderate to severe 
intensity per month in the 3 months prior to the Screening Visit, and at 
least 6 migraine days and no more than 18 headache days during the
28-day Observation Period which will be documented in the eDiary.
Upon completion of the Screening visit, subjects will be provided an
electronic diary (eDiary) to document each day of the 28-day 
Observation Period if a migraine occurred and the migraine intensity.  
Subjects will record the standard of care migraine treatment received
on a paper diary and female subjects will record their menstrual period
information on a paper log. After completing the 28-day Observation 
Period, the subject will return to the clinic with both diaries for the 
Baseline Visit. 
Subjects will have blood drawn for baseline lab profiles at the
Pre-Randomization Lab Visit; this visit must occur within 96 hours (4 
days) of the Baseline Visit. Sites are encouraged to complete this visit 
within 96 hours (4 days) of the Baseline Visit, however, if scheduling 

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 12 of 91
challenges arise, site staff may use an additional +2 day window for 
this visit to occur within 144 hours (or 4 days, +2 days). Subjects will 
then return for the Baseline (Randomization) Visit.  
At the Baseline Visit, eligibility for continued participation in the study 
will be assessed before randomization occurs and before study 
medication is dispensed.  Subjects will be instructed that they must 
take one tablet of blinded study drug every other calendar day. If 
subjects have a migraine during the double-blind phase of the study, if 
needed, they may treat the migraine with their standard of care 
medication and continue to take study medication on their regular 
schedule (scheduled dosing days only).
At the completion of the 12-week double-blind, treatment phase, 
subjects will be evaluated for entry into the 52-week open-label,
extension phase following laboratory results within acceptable ranges
per protocol (Table 2).  During the open-label, extension phase, 
subjects will be instructed that they must take one tablet of study 
medication every other calendar day.  If subjects have a migraine on a 
day that they are not scheduled to dose with study drug, they may take 
one tablet of rimegepant on that calendar day to treat a migraine.  
Therefore, during the open-label, extension phase, subjects can take a 
maximum of one tablet of study drug per calendar day for this 52-week 
period.
Subjects are required to record their migraine occurrence and severity 
and all study medication doses in the eDiary. Subjects are also required 
to record the rescue medication taken on a paper diary and female 
subjects will record their menstrual period information on a paper log. 
Subjects will also use the eDiary to complete the Preference of 
Medication (PoM) and the Satisfaction with Medication (SM) scales at 
specified study timepoints.
At select study visits, subjects will complete or will be administered 
the Migraine-Specific Quality-of-Life Questionnaire v 2.1 (MSQ v 
2.1), the Migraine Disability Assessment (MIDAS), Clinical Global 
Impression – change (CGI-c) scale, and the Sheehan Suicidality 
Tracking Scale (S-STS) on paper forms.
Additional assessments and visit schedule are outlined in the
procedural table in Section 4.3.  Procedures include study personnel 
review of the eDiary and paper diary with the subject, assessment of 
study medication compliance, monitoring of tolerability and safety 
(including vital signs, laboratory tests, and electrocardiography).  

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 13 of 91
Study visits will occur at Screening (Enrollment), Pre-Randomization 
Lab Visit which should occur within 96 hours (+48 hours) of the 
Baseline Visit, Baseline (Randomization), Week 2, Week 4, Week 8, 
and Week 12.  At the completion of the 12-week double-blind,
treatment phase, subjects will be evaluated for entry into the 52-week 
open-label, extension phase following laboratory results within 
acceptable ranges per protocol (Table 2). Visits occur at Week 14, 16, 
20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64 / End of Treatment (EOT).  
Subjects will return to the study site at the end of Week 64 for the End 
of Treatment (EOT) Visit. There is a Follow-up Visit 14 days after the 
EOT Visit and 8 weeks after the EOT visit for assessment of LFTs.  
Subjects who do not complete the Double-blind, Treatment Phase 
and/or do not enter or complete the Open-label, Extension Phase 
should complete the End of Treatment Visit, the 2-Week Follow-up 
Safety Visit, and the 8-Week Follow-up Safety Visit.
To closely monitor for potential drug induced liver injury, guidance on 
reporting potential drug-induced liver injury (DILI) events is provided 
in the protocol. Lab results that meet predefined LFT abnormality 
criteria as potential DILI events should be reported as a serious adverse 
event (SAE). See Section 8.1.5 Potential Drug Induced Liver Injury 
(DILI).
Primary 
Endpoint: 
Change from baseline (observation period) in the mean number of
migraine days per month in the last four weeks (Weeks 9 to 12) of the 
double-blind treatment phase.
Secondary 
Endpoints:
Achievement of at least a 50% reduction from baseline in the mean 
number of moderate to severe migraine days per month in the last 4 
weeks of the double-blind treatment phase.
Change from baseline in the mean number of migraine days per month
over the entire double-blind treatment phase (Weeks 1 to 12).
The mean number of rescue medication days per month in the last 4 
weeks of the double-blind treatment phase.  Rescue medications 
include the rescue medications defined in this protocol (please refer to 
Section 5.5)
Change from baseline in the mean number of migraine days per month 
in the first 4 weeks (Weeks 1 through 4) of the double-blind treatment 
phase.

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 14 of 91
The frequency of unique subjects with adverse events, serious adverse 
events, adverse events leading to discontinuation and clinically 
significant laboratory test abnormalities from case report forms and 
clinical laboratory evaluations. 
The frequency of unique subjects with AST or ALT elevations > 3x 
ULN, concurrently with bilirubin elevations > 2x ULN.
The frequency of unique subjects with hepatic-related adverse events 
and hepatic-related adverse events leading to treatment discontinuation 
from case report forms. 
The mean change from baseline in the MSQ role function - restrictive 
domain score at Week 12 of the double-blind treatment phase.
The mean change from baseline in MIDAS total score at Week 12 of 
the double-blind treatment phase.

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 15 of 91
STUDY SCHEMATIC
Up to 12 weeks of double-blind treatment with every other day
dosing, followed by up to 52 weeks of open-label treatment with at least
every other day dosing
Start taking O-L  Medication 
or Subject to Return Study 
Medication 
Screen-
ing Visit 
Baseline 
Visit 
(Random-
ization)
12 week Double-blind 
Treatment Period 
End of 
Double-
blind 
Phase  
(Week 
12)/ 
Screening 
for Open-
label 
Phase or 
Early D/C 
Visit
Follow-
up Visits: 
14 days 
(+/- 2 
days)  
and 8
weeks (-2 
days to   
+14 days)
from EOT 
or Early 
D/C Visit
Up to 76 Weeks
Dispense and start 
taking study 
medication 
Stop Taking Study 
Double-blind 
Medication 
Rimegepant 
75 mg  EOD
Dosing
Placebo  
EOD
Dosing
Pre-
Rand 
Lab Visit 
for 
Double-
blind 
Phase: 
within 
96 hours
(+48 
hours)
of 
Baseline
28-Day Observation 
Period: Screening Visit to 
Baseline Visit
Contact 
Subject:  
Inform  
subject of 
eligibility 
to start 
dosing 
with study 
medication 
or 
ineligibility 
for open-
label phase  
52 week 
Open-label  
(O-L) 
Treatment 
Period 
Rimegepant 
75 mg  EOD
Dosing
/
k
\
 >
/
1

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 16 of 91
TABLE OF CONTENTS
1
INTRODUCTION AND RATIONALE ..........................................................................23
1.1
BACKGROUND..........................................................................................................23
1.2
CGRP’S ROLE IN MIGRAINE.................................................................................23
1.3
PRODUCT DEVELOPMENT BACKGROUND.......................................................24
1.3.1
CLINICAL ADVERSE EVENT PROFILE .........................................................24
1.4
STUDY RATIONALE.................................................................................................24
1.4.1
STUDY DESIGN RATIONALE ...........................................................................25
1.4.2
DOSE SELECTION ..............................................................................................25
1.5
RESEARCH HYPOTHESIS.......................................................................................25
2
STUDY OBJECTIVES ....................................................................................................26
2.1
PRIMARY ...................................................................................................................26
2.2
SECONDARY..............................................................................................................26
3
STUDY ENDPOINTS ......................................................................................................29
3.1
PRIMARY ...................................................................................................................29
3.2
SECONDARY..............................................................................................................29
3.3
MEASURES OF INTEREST......................................................................................29
3.4
DEFINITION OF MIGRAINE DAYS .......................................................................30
3.5
DEFINITION OF HEADACHE DAYS......................................................................30
4
STUDY PLAN ..................................................................................................................31
4.1
STUDY DESIGN AND DURATION..........................................................................31
4.2
STUDY SCHEMATIC ................................................................................................33
4.3
SCHEDULE OF ASSESSMENTS..............................................................................34
4.3.1
SCREENING VISIT / OBSERVATION PERIOD (28 DAYS)............................42
4.3.1.1
PRE-RANDOMIZATION (LABORATORY) VISIT ....................................42
4.3.2
RANDOMIZED, DOUBLE-BLIND TREATMENT PHASE (12 WEEKS) .......43
4.3.3
OPEN-LABEL EXTENSION PHASE (52 WEEKS) ...........................................43
4.3.4
END OF TREATMENT (WEEK 64)....................................................................44
4.3.5
2-WEEK FOLLOW UP SAFETY VISIT .............................................................45
4.3.6
8-WEEK FOLLOW UP SAFETY VISIT .............................................................45
4.4
POST STUDY ACCESS TO THERAPY (IF APPLICABLE) ..................................45
5
POPULATION.................................................................................................................46
5.1
NUMBER OF SUBJECTS..........................................................................................46
5.2
INCLUSION CRITERIA............................................................................................46
5.3
EXCLUSION CRITERIA...........................................................................................47
5.4
PROHIBITED CONCOMITANT MEDICATION ...................................................52
5.5
PROPHYLACTIC AND RESCUE MEDICATIONS................................................53
5.6
WOMEN OF CHILDBEARING POTENTIAL.........................................................55
5.7
OTHER RESTRICTIONS AND PRECAUTIONS (IF APPLICABLE)...................55
5.8
DEVIATION FROM INCLUSION/EXCLUSION CRITERIA AND STUDY 
PROCEDURES ...........................................................................................................55

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 17 of 91
6
STUDY CONDUCT AND DESCRIPTION OF STUDY PROCEDURES ....................56
6.1
STUDY MATERIALS.................................................................................................56
6.2
SAFETY ASSESSMENTS ..........................................................................................57
6.2.1
VITAL SIGNS AND PHYSICAL MEASUREMENTS (HEIGHT AND 
WEIGHT) ..............................................................................................................57
6.2.2
ELECTROCARDIOGRAM (ECG)......................................................................57
6.2.3
PHYSICAL EXAM................................................................................................57
6.2.4
LABORATORY ASSESSMENTS........................................................................58
6.2.4.1
SAFETY LABORATORY TESTING.............................................................58
6.2.4.2
PREGNANCY TESTING................................................................................58
6.2.5
SHEEHAN SUICIDALITY TRACKING SCALE...............................................59
6.3
EFFICACY ASSESSMENTS......................................................................................59
6.4
OTHER ASSESSMENTS ...........................................................................................59
6.4.1
MIGRAINE-SPECIFIC QUALITY-OF-LIFE QUESTIONNAIRE V 2.1 .........59
6.4.4
MIGRAINE DISABILITY ASSESSMENT (MIDAS) QUESTIONNAIRE........60
6.5
EARLY DISCONTINUATION FROM THE STUDY...............................................60
7
STUDY DRUG MANAGEMENT ...................................................................................62
7.1
DESCRIPTION OF STUDY DRUG...........................................................................62
7.1.1
INVESTIGATIONAL PRODUCT .......................................................................62
7.1.2
NON-INVESTIGATIONAL PRODUCT..............................................................62
7.1.3
PACKAGING, SHIPMENT AND STORAGE.....................................................62
7.2
DOSE AND ADMINISTRATION ..............................................................................63
7.2.1
METHOD OF ASSIGNING SUBJECT IDENTIFICATION..............................63
7.2.2
SELECTION AND TIMING OF DOSE AND ADMINISTRATION..................63
7.2.3
DOSE MODIFICATION.......................................................................................64
7.2.4
DOSE INTERRUPTIONS.....................................................................................64
7.3
BLINDING AND UNBLINDING ...............................................................................64
7.4
TREATMENT COMPLIANCE .................................................................................64
7.5
DESTRUCTION AND RETURN OF STUDY DRUG...............................................65
8
ADVERSE EVENTS........................................................................................................66
8.1
SERIOUS ADVERSE EVENT ...................................................................................66
8.1.1
DEFINITION OF SERIOUS ADVERSE EVENT (SAE) ....................................66
8.1.2
COLLECTION AND REPORTING SERIOUS ADVERSE EVENTS...............68
8.1.3
OVERDOSE...........................................................................................................69
8.1.4
PREGNANCY........................................................................................................70
8.1.5
POTENTIAL DRUG INDUCED LIVER INJURY (DILI)..................................70
8.2
NON-SERIOUS ADVERSE EVENTS........................................................................71
8.2.1
COLLECTION AND REPORTING OF NON-SERIOUS ADVERSE 
EVENTS.................................................................................................................71
8.2.2
LABORATORY TEST ABNORMALITIES........................................................71
9
STATISTICS....................................................................................................................72

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 18 of 91
9.1
GENERAL PROCEDURES .......................................................................................72
9.2
POPULATIONS FOR ANALYSIS.............................................................................72
9.3
SAMPLE SIZE ............................................................................................................73
9.4
PRIMARY ENDPOINT ..............................................................................................73
9.5
SECONDARY ENDPOINT(S)....................................................................................73
9.6
MULTIPLICITY CORRECTION .............................................................................74
9.7
DEMOGRAPHIC AND BASELINE CHARACTERISTICS....................................75
9.8
SCHEDULE OF ANALYSES.....................................................................................75
10 ETHICS AND RESPONSIBILITIES..............................................................................76
10.1
GOOD CLINICAL PRACTICE.................................................................................76
10.2
DATA AND SAFETY MONITORING COMMITTEE ............................................76
10.3
INFORMED CONSENT.............................................................................................76
10.4
CASE REPORT FORMS............................................................................................78
10.5
RECORDS MANAGEMENT AND RETENTION....................................................78
10.6
SOURCE DOCUMENTATION .................................................................................79
10.7
STUDY FILES AND RECORD RETENTION..........................................................79
11 AMENDMENTS ..............................................................................................................80
12 STUDY REPORT AND PUBLICATIONS.....................................................................81
13 STUDY DISCONTINUATION .......................................................................................82
14 CONFIDENTIALITY......................................................................................................83
15 APPENDICES..................................................................................................................84
15.1
APPENDIX 1 - NAMES OF STUDY PERSONNEL .................................................84
15.2
APPENDIX 2 – INHIBITORS AND INDUCERS OF CYP3A4 OR CYP2C9 (NOT 
ALL-INCLUSIVE) ......................................................................................................85
15.3
APPENDIX 3 – DEFINITION OF MIGRAINE DAYS.............................................87
15.4
APPENDIX 4 – CATEGORIES OF MIGRAINE PREVENTION 
MEDICATIONS..........................................................................................................89
16 REFERENCES.................................................................................................................90

Protocol BHV3000-305
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 19 of 91
LIST OF TABLES
Table 1.
Schedule of Assessments – Double-Blind Treatment Phase9, 10 ......................34
Table 2.
Schedule of Assessments – Open-label Extension Phase Including End of 
Treatment (EOT)10 & Follow-up Visits...........................................................38
LIST OF FIGURES
Figure 1.
Up to 12 Weeks of Double-blind Treatment with Every Other Day Dosing, 
Followed by Up To 52 Weeks of Open-label Treatment with at Least Every 
Other Day (EOD) Dosing.................................................................................33

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 20 of 91
LIST OF ABBREVIATIONS
AE
Adverse Event
ALT
Alanine Aminotransferase
AST
Aspartate Aminotransferase
AUC
Area Under the Curve
bid
Twice Daily
BP
Blood Pressure
BUN
Blood Urea Nitrogen
Cmax
Maximum Plasma Concentration
CONMED
Concomitant Medication
CRF
CRPS
Case Report Form
Complex Regional Pain Syndrome
CTCAE
Common Terminology Criteria for Adverse Events
CV
Coefficient of Variation
DILI
Drug-Induced Liver Injury
DSMC
Data and Safety Monitoring Committee
DSM-V
Diagnostic and Statistical manual of Mental Disorders Fifth edition
ECG
EDC
EOD
Electrocardiogram
Electronic Data Capture
Every Other Day
FAS
Full analysis set
FSH
Follicle Stimulating Hormone

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 21 of 91
GCP
Good Clinical Practice
HIV
Human Immunodeficiency Virus
HR
Heart Rate
ICF
Informed Consent Form
IB
Investigator’s Brochure
ICH
International Conference on Harmonization
ICF
Informed Consent Form
IEC
Independent Ethics Committee
HIS
International Headache Society
INR
International Normalized Ratio
IRB
Institutional Review Board
IV
Intravenous
IWRS
Interactive Web Response System
kBq
Kilobecquerel
kg
Kilogram
L
Liters
LFTs
Liver Function Tests
MBq
MDZ
Megabecquerel
Midazolam
mg
Milligram
MIDAS
Migraine Disability Assessment
MSQ
Migraine-Specific Quality-of-Life Questionnaire 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 22 of 91
min
Minute
mmHg
Millimeters Mercury
NOEL
No Observed Effect Level
NOAEL
O-L
No Observed Adverse Event Level
Open-label
PK
Pharmacokinetic
PO
By Mouth, Orally
QD
Once Daily
QTc
Interval between Q-wave and T-wave in the cardiac cycle
SAE
Serious Adverse Event
S-SST
Sheehan Suicidality Tracking scale
ULN
Upper Limit of Normal
WBC
White Blood Cell
WHO
World Health Organization
WOCBP
Women of Childbearing Potential

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 23 of 91
1
INTRODUCTION AND RATIONALE
1.1
Background
Migraine is a common and debilitating neurological disorder that affects approximately 15% of 
the adult population. It is characterized by moderate-to-severe episodic unilateral pulsating 
headaches that last for 4 to 72 hours. Typical characteristics of the headache are unilateral 
location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity, 
and association with nausea and/or photophobia and phonophobia.1 BHV-3000 (rimegepant) is a 
calcitonin gene-related peptide (CGRP) receptor antagonist in development for the acute 
treatment of migraine. The CGRP receptor is located within pain-signaling pathways, 
intracranial arteries and mast cells and its activation is thought to play a causal role in migraine 
pathophysiology. For example, research and clinical studies have shown: serum levels of CGRP 
are elevated during migraine attacks, infusion of intravenous CGRP produces persistent pain in 
migraine sufferers and non-migraine sufferers, and treatment with anti-migraine drugs normalize 
CGRP levels. Additionally, multiple clinical studies show that small molecule CGRP receptor 
antagonists, which inhibit the binding of endogenous CGRP to CGRP receptors, are effective in 
aborting migraine attacks. Treatment with a CGRP receptor antagonist is believed to relieve 
migraine through the possible mechanisms of 1) blocking neurogenic inflammation, 2)
decreasing artery dilation, and 3) inhibiting pain transmission. There is widespread agreement 
that this new approach avoids the cardiovascular effects produced by active vasoconstriction 
associated with the current standard triptan therapy (non-selective 5-HT1B/1D agonists (e.g., 
sumatriptan [Imitrex™])).
1.2
CGRP’s Role in Migraine
The CGRP receptor is located within pain-signaling pathways, intracranial arteries and mast cells 
and its activation is thought to play a causal role in migraine pathophysiology. For example, 
research and clinical studies have shown: serum levels of CGRP are elevated during migraine 
attacks, infusion of intravenous CGRP produces persistent pain in migraine sufferers and non-
migraine sufferers, and treatment with anti-migraine drugs normalize CGRP levels. Additionally, 
multiple clinical studies show that small molecule CGRP receptor antagonists, which inhibit the 
binding of endogenous CGRP to CGRP receptors, are effective in aborting migraine attacks.
Treatment with a CGRP receptor antagonist is believed to relieve migraine through the following 
possible mechanisms:

Blocking Neurogenic Inflammation: Binding of CGRP receptor antagonists to CGRP 
receptors located on mast cells would inhibit inflammation caused by trigeminal nerve 
release of CGRP onto mast cells within the tough outer covering of the brain, or the 
meninges.

Decreasing Artery Dilation: By blocking the CGRP receptors located in smooth muscle 
cells within vessel walls, CGRP receptor antagonists would inhibit the pathologic dilation 
of intracranial arteries without the unwanted effect of active vasoconstriction.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 24 of 91

Inhibiting Pain Transmission: Binding of CGRP receptor antagonists to CGRP 
receptors would suppress the transmission of pain by inhibiting the central relay of pain 
signals from the trigeminal nerve to the caudal trigeminal nucleus.
1.3
Product Development Background
Details of the clinical and preclinical studies are provided in the most current Investigator 
Brochure. A summary of the relevant data to the study are presented below. 
1.3.1
Clinical Adverse Event Profile  
Rimegepant appears to be generally safe and well tolerated in humans when given as single oral 
doses up to the maximum dose of 1500 mg and multiple oral doses up to the maximum daily 
dose of 600 mg for 14 days. The ongoing BHV3000-201 study is a Phase 2/3, 52-week, open-
label, safety study with rimegepant 75 mg that is designed to enroll approximately 2000 subjects
to receive rimegepant up to once daily. Please refer to the Investigators Brochure for a summary 
of the clinical safety profile. 
The primary identified AE of interest is potential change in liver function tests. Investigators 
must carefully monitor routine liver function tests (ALT, AST, total bilirubin, and ALP) and 
potentially liver related symptoms and signs. Clinicians should  also monitor changes in 
hematology and other laboratory measures. Please refer to the current Investigators Brochure for 
further information regarding the clinical safety profile of rimegepant.
1.4
Study Rationale
The demonstrated efficacy of rimegepant in the three pivotal Phase 3 registrational trials in the 
acute treatment of migraine and the safety profile observed to date in the Phase 2/3 BHV3000-
201 long-term open-label safety study with up to daily dosing for as long as 1 year suggest that 
rimegepant may have an important role in the treatment of migraine.
This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant for 
the prevention of migraine. It will also further define the safety profile of rimegepant
administration for as long as 64 weeks. Approximately 800 subjects will dose with blinded study 
drug at least every other day for a period of approximately 12 weeks, followed by an additional 
52 weeks with open-label rimegepant with scheduled dosing every other day as well.  During the 
open-label portion of the study, on days without scheduled rimegepant dosing, subjects may take 
up to 1 tablet of rimegepant per calendar day as needed for acute treatment of migraine.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 25 of 91
1.4.1
Study Design Rationale
This is a 12-week multicenter, randomized, double-blind, placebo controlled evaluation of the 
safety and efficacy of rimegepant 75 mg tablet taken every other day for the prevention of 
migraine with a 52-week open-label extension phase. Up to approximately 800 subjects will be 
randomized and assigned treatment in the double-blind phase of the study; it is estimated that 
approximately 675 subjects will enter the open-label phase of the study. During the double-blind 
phase, subjects will be instructed that they must take one tablet of blinded study drug every other 
calendar day. If subjects have a migraine during the double-blind phase of the study, if needed, 
they may treat the migraine with their standard of care medication and continue to take study 
medication on their regular schedule (scheduled dosing days only).
During the open-label phase of the study, subjects will be required to take one tablet of 
rimegepant every other calendar day.  However, if subjects have a migraine on a day that they 
are not scheduled to dose with rimegepant, they may take 1 tablet of rimegepant on that calendar
day to treat the migraine. Dosing with more than 1 tablet of study medication per calendar day is 
not permitted. Therefore, subjects can take a maximum of one tablet of study drug per calendar 
day for the 52 weeks of the open-label phase.
The study will randomize approximately 800 subjects and it is expected that approximately 675 
subjects will enter the open-label phase of the study. During the double-blind phase, the subjects 
will be randomized in a 1:1 ratio to the rimegepant or placebo treatment groups, stratified by
current use of prophylactic migraine medications (yes or no).
1.4.2
Dose Selection 
The Phase 2b dose-ranging study CN170003 established that rimegepant 75 mg is the minimum 
effective dose for the acute treatment of migraine. The three Phase 3 studies BHV3000-301, 
BHV3000-302, and BHV3000-303 confirmed this efficacy using the current registrational 
endpoints for acute treatment of migraine. In addition, several CGRP antagonists have been 
shown to be effective for the prevention of migraine.  This observation and the flat dose-response 
with rimegepant and other CGRP receptor antagonists suggest that rimegepant 75 mg every other 
day (EOD) may be an effective dose for the prevention of migraine.  The pharmacokinetic 
profile of rimegepant supports the dosing schedule of this protocol with up to daily dosing.
1.5
Research Hypothesis
Rimegepant is safe and effective treatment for the prevention of migraine.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 26 of 91
2
STUDY OBJECTIVES
2.1
Primary

To compare the efficacy of rimegepant to placebo as a preventive treatment for migraine, as 
measured by the reduction from baseline in the mean number of migraine days per month in 
the last four weeks of the double-blind treatment phase.  (A month is defined as 4 weeks for 
the purpose of this protocol). 
2.2
Secondary

To compare the efficacy of rimegepant to placebo on the proportion of subjects that have at 
least a 50% reduction from baseline in the mean number of moderate to severe migraine days 
per month in the last 4 weeks of the double-blind treatment phase.  

To compare the efficacy of rimegepant to placebo on the reduction from baseline in the mean 
number of migraine days per month over the entire course of the double-blind treatment 
phase.

To compare the frequency of use of rescue medications between the rimegepant and placebo 
in the last 4 weeks of the double-blind treatment phase.

To compare the efficacy of rimegepant to placebo on the reduction from baseline in the mean 
number of migraine days per month in the first 4 weeks of the double-blind treatment phase.

To evaluate the safety and tolerability of rimegepant.

To evaluate the frequency of ALT or AST > 3x ULN with concurrent elevations in bilirubin 
> 2x ULN in subjects treated with rimegepant.

To evaluate the frequency of hepatic-related adverse events and the frequency of hepatic-
related treatment discontinuations in subjects treated with rimegepant.

To compare the change from baseline in the Migraine-Specific Quality-of-Life Questionnaire 
v 2.1 (MSQ) role function - restrictive domain score at Week 12 of the double-blind 
treatment phase between rimegepant and placebo.

To compare the change from baseline in the Migraine Disability Assessment (MIDAS) total 
score at Week 12 of the double-blind treatment phase between rimegepant and placebo.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 27 of 91
 
 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 28 of 91

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 29 of 91
3
STUDY ENDPOINTS 
3.1
Primary

Change from baseline (observation period) in the mean number of migraine days per month
in the last 4 weeks (Weeks 9 through 12) of the double-blind treatment phase.
3.2
Secondary

Achievement of at least a 50% reduction from baseline in the mean number of moderate to 
severe migraine days per month in the last 4 weeks of the double-blind treatment phase.

Change from baseline in the mean number of migraine days per month over the entire 
double-blind treatment phase (Weeks 1 to 12).

The mean number of rescue medication days per month in the last 4 weeks of the double-
blind treatment phase.  Rescue medications allowed in the 2 phases of this study are specified 
in Protocol Section 5.5.

Change from baseline in the mean number of migraine days per month in the first 4 weeks 
(Weeks 1 through 4) of the double-blind treatment phase.

The frequency of unique subjects with adverse events, serious adverse events, adverse events 
leading to discontinuation and clinically significant laboratory test abnormalities, from case 
report forms and clinical laboratory evaluations. 

The frequency of unique subjects with of AST or ALT elevations > 3x ULN, concurrently 
with bilirubin elevations > 2x ULN. 

The frequency of unique subjects with hepatic-related adverse events and hepatic-related 
adverse events leading to treatment discontinuation from case report forms. 

The mean change from baseline in the MSQ role function - restrictive domain score at Week 
12 of the double-blind treatment phase.

The mean change from baseline in the MIDAS total score at Week 12 of the double-blind 
treatment phase.
3.3
Measures of Interest
Not Applicable

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 30 of 91
3.4
Definition of Migraine Days
A Migraine Day is defined as any calendar day which the subject experiences a qualified 
migraine headache (onset, continuation or recurrence of the migraine headache).  A qualified 
migraine headache is defined as a migraine with or without aura, lasting for ≥30 minutes, and 
meeting at least one of the following criteria (A and/or B): 
A) ≥ 2 of the following pain features: 

Unilateral location,

Pulsating quality (throbbing),

Moderate or Severe pain intensity, 

Aggravation by or causing avoidance of routine physical activity (e.g. walking or 
climbing stairs)
B) ≥ 1 of the following associated symptoms: 

Nausea and/or Vomiting, 

Photophobia and phonophobia
During the double-blind, treatment phase, if the subject takes a migraine-specific medication (i.e.
triptan or ergotamine) during aura or to treat a headache on a calendar day, then it will be 
counted as a migraine day regardless of the duration and pain features/associated symptoms. The 
use of study medication on non-scheduled dosing days is only permitted during the open-label, 
extension phase. Dosing with study medication on non-scheduled dosing days is not permitted 
during the double-blind, treatment phase.
A moderate to severe migraine day is a migraine day with a migraine reported with moderate or 
severe pain intensity.
For the full definition of Migraine Days, please refer to Section 15.3 Appendix 3.
3.5
Definition of Headache Days
A Headache Day is any calendar day in which the subject experiences a qualified headache 
(initial onset, continuation, or recurrence of the headache). A qualified headache is defined as:

A qualified migraine headache (including an aura-only event that is treated with acute 
migraine-specific medication), or

A qualified non-migraine headache, which is a headache that lasts ≥ 30 minutes and is not a 
qualified migraine headache, or

A headache of any duration for which acute headache treatment is administered.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 31 of 91
4
STUDY PLAN
4.1
Study Design and Duration
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy 
and safety of rimegepant in migraine prevention with an open-label extension phase.   
The Screening phase includes a screening visit and a 28-day Observation Period. For subjects to 
be eligible for the study, they must have reported having had 4-18 migraine attacks of moderate 
to severe intensity per month in the 3 months prior to the Screening Visit, and at least 6 migraine 
days and no more than 18 headache days during the 28-day Observation Period which will be 
documented in the eDiary.
Upon the completion of the screening visit, subjects will be provided an electronic diary (eDiary)
to document each day of the 28-day Observation Period if a migraine occurred, the migraine 
intensity and if the migraine was treated. Subjects will record the standard of care migraine 
treatment received on a paper diary and female subjects will record their menstrual period
information on a paper log. After completing the 28-day Observation Period, the subject will 
return to the clinic with both diaries for the Baseline Visit. 
Subjects will have blood drawn for baseline lab profiles at the Pre-Randomization Lab Visit; this 
visit must occur within 96 hours (4 days) of the Baseline Visit.  Sites are encouraged to complete 
this visit within 96 hours (4 days) of the Baseline Visit, however, if scheduling challenges arise, 
site staff may use an additional +2 day window for this visit to occur within 144 hours (or 4 
days, +2 days).  Subjects will then return for the Baseline (Randomization) Visit.  
At the Baseline Visit, eligibility for continued participation in the study will be assessed before 
randomization occurs and study medication will be dispensed. Subjects will be instructed that 
they must take one tablet of blinded study drug every other calendar day. If subjects have a 
migraine during the double-blind phase of the study, if needed, they may treat the migraine with 
their standard of care medication and continue to take study medication on their regular schedule 
(scheduled dosing days only).
At the completion of the 12-week double-blind phase, subjects may be entered into the 52-week 
open-label phase following laboratory test results within acceptable ranges per protocol (Table 
2).  During the open-label, extension phase, subjects will be instructed that they must take one 
tablet of study medication every other calendar day.  If subjects have a migraine on a day that 
they are not scheduled to dose with study drug, they may take 1 tablet of rimegepant on that 
calendar day to treat a migraine.  During the open-label, extension phase, subjects can take a 
maximum of one tablet of study drug per calendar day for this 52-week period.
Subjects are required to record their migraine occurrence and severity and all study medication 
doses in the eDiary. Subjects are also required to record the rescue medication taken on a paper 
diary and female subjects will record their menstrual period information on a paper log. 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 32 of 91
 
At select study visits, subjects will complete or will be administered the Migraine-Specific
Quality-of-Life Questionnaire v 2.1 (MSQ v 2.1), the Migraine Disability Assessment (MIDAS), 
, and the Sheehan Suicidality Tracking Scale 
(S-STS) on paper forms. 
Additional assessments and visit schedule are outlined in the procedural table in Section 4.3. 
Procedures include study personnel review of the eDiary and paper diary with the subject, 
assessment of study medication compliance, monitoring of tolerability and safety (including vital 
signs, laboratory tests, and electrocardiography).  
Study visits will occur at Screening (Enrollment), Pre-Randomization Lab Visit which must 
occur within 96 hours (+48 hours) of the Baseline Visit, Baseline (Randomization), Week 2, 
Week 4, Week 8, and Week 12.  At the completion of the 12-week double-blind phase, Subjects
may enter into the 52-week open-label phase if they continue to meet study entry criteria and
laboratory test results are acceptable per protocol (See Exclusion Criterion 8 in Section 5.3)
(Table 2). Visits occur at Week 14, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64 / End of 
Treatment (EOT).  Subjects will return to the study site at the end of Week 64 for the End of 
Treatment (EOT) Visit. There is a Follow-up Visit 14 days after the EOT Visit and 8 weeks after 
the EOT visit for assessment of LFTs.  Subjects who do not complete the Double-blind, 
Treatment Phase and/or do not enter or complete the Open-label, Extension Phase should 
complete the End of Treatment Visit, the 2-Week Follow-up Safety Visit, and the 8-Week
Follow-up Safety Visit.
To closely monitor for potential drug induced liver injury, guidance on reporting potential drug-
induced liver injury (DILI) events is provided in the protocol. Lab results that meet predefined 
LFT abnormality criteria as DILI should be reported as a serious adverse event (SAE). See 
Section 8.1.5, Potential Drug Induced Liver Injury (DILI).

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 33 of 91
4.2
Study Schematic
Figure 1.
Up to 12 Weeks of Double-blind Treatment with Every Other Day Dosing, Followed by Up To 52
Weeks of Open-label Treatment with at Least Every Other Day (EOD) Dosing
Screening 
Visit 
Baseline 
Visit 
(Random-
ization)
12 week Double-blind 
Treatment Period 
End of 
Double-
blind 
Phase  
(Week 
12)/ 
Screening 
for Open-
label 
Phase or 
Early D/C 
Visit
Follow-
up Visits: 
14 days 
(+/- 2 
days)  
and 8 
weeks (-2 
days to + 
14 days)
from EOT 
or Early 
D/C Visit
Up to 76 Weeks
Dispense and start 
taking study 
medication 
Stop Taking Study 
Double-blind 
Medication 
Rimegepant 
75 mg  EOD
Dosing
Placebo  
EOD
Dosing
Pre-
Rand 
Lab Visit 
for 
Double-
blind 
Phase: 
within 
96 hours
(+48 
hours) of 
Baseline
28-Day Observation 
Period: Screening Visit to 
Baseline Visit
Contact 
Subject:  
Inform  
subject of 
eligibility to 
start 
dosing with 
study 
medication 
or 
ineligibility 
for open-
label phase  
52 week 
Open-label  
(O-L) 
Treatment 
Period 
Start taking O-L  Medication 
or Subject to Return Study 
Medication 
Rimegepant 
75 mg  EOD
Dosing
_
_
/
‘
\
 >
/
1
_
12

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 34 of 91
4.3
Schedule of Assessments
Table 1.
Schedule of Assessments – Double-Blind Treatment Phase9, 10
Procedure
Screening 
Visit
Observation 
Period10
(28 days, + 3
days)
Pre-Randomization 
Laboratory Visit: must 
occur within 96 hours of
Baseline (Randomization)
Visit11
Baseline 
(Randomization) 
Visit (Day 1)
Week 2   
(Day 14 +/-
2 days)
Week 4
(Day 28     
+3 days)
Weeks 8 (Day 
56) and 12
(Day 84)
(all visits + 3 
days)
Eligibility Assessments
Informed Consent
X
 
X
Inclusion/Exclusion Criteria
X
X
Medical History
X
Migraine History 
(signs/symptoms/prior 
treatment/frequency/intensity)
X
Rescue Medication paper diary, 
Concomitant Medication paper 
diary and Menstrual Period 
paper log (female subjects)1
X
X
X
X
X
X
X
Randomize subject / IWRS2
X
Safety Assessments
Physical Examination
X
X
X
X
Vital Signs / Physical 
Measurements3
X
X
X
X

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 35 of 91
Procedure
Screening 
Visit
Observation 
Period10
(28 days, + 3
days)
Pre-Randomization 
Laboratory Visit: must 
occur within 96 hours of
Baseline (Randomization)
Visit11
Baseline 
(Randomization) 
Visit (Day 1)
Week 2   
(Day 14 +/-
2 days)
Week 4
(Day 28     
+3 days)
Weeks 8 (Day 
56) and 12
(Day 84)
(all visits + 3 
days)
Clinical Safety Laboratory 
Testing
X
X
X
X
Liver Function Test (LFTs)
X
X
X
X
X
X
Lipid Panel
X
ECG
X
X
X
Urinalysis
X
Urine Drug Screen for drugs of 
abuse
X
FSH, if applicable, to determine 
WOCBP status
X
Pregnancy Test
X (urine)
X (serum)
X (urine)
X (urine)
X (urine)
AE, SAE, and Concomitant 
Procedure assessment4
X
X
X
X
X
X
Sheehan Suicidality Tracking 
Scale
X
X
X
X
X
Clinical Drug Supplies / Study 
Supplies
Dispense Study Medication5
X
X
X
Administer study medication6
X
X
X
Electronic Diary (eDiary) 
dispensed
X

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 36 of 91
Procedure
Screening 
Visit
Observation 
Period10
(28 days, + 3
days)
Pre-Randomization 
Laboratory Visit: must 
occur within 96 hours of
Baseline (Randomization)
Visit11
Baseline 
(Randomization) 
Visit (Day 1)
Week 2   
(Day 14 +/-
2 days)
Week 4
(Day 28     
+3 days)
Weeks 8 (Day 
56) and 12
(Day 84)
(all visits + 3 
days)
Enter use of study medication in 
eDiary
X
X
X
X
Return unused study medication 
to site for compliance check
X
X
X
eDiary returned / reviewed for 
completness7
X
X
X
X
X
X
Other Assessments
Daily report of migraine 
occurrence and severity 
reported by subject in eDiary8
X
X
X
X
X
X
Migraine-Specific Quality-of-
Life Questionnaire (MSQ) v 2.1
X
X (week 12 
only)
 
 
 
 
 
Migraine Disability Assessment 
(MIDAS)
X
X (week 12 
only)
1 Concomitant medications, including prophylactic and standard of care migraine medications, taken during Observation Period and rescue medication taken 
during the Treatment Phase should be recorded in the subject’s paper diary and reviewed by study personnel at each visit. Female subjects will also record 
menstrual period information on the paper diary which should be reviewed by study personnel at each visit.
2 The actual baseline visit date should be used for IWRS enrollment date and eligibility date.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 37 of 91
3 Height measured at Screening Visit only.  Weight, body temperature, respiratory rate, blood pressure, and heart rate will be collected at all timepoints where 
indicated.  Sitting arterial systolic and diastolic blood pressure and radial artery pulse rate will be measured.
4 SAEs, AEs, and Concomitant Procedures must be reported after subject signs informed consent.  SAEs should be reported from signing of consent through the 
8-week Follow up Safety Visit.  Non-serious AEs should be reported from signing of consent through 2-Week Follow up Safety Visit. 
5 Subjects should finish a bottle of study medication before starting a new bottle.  Study drug will be dispensed at monthly (every 4 weeks) study visits, as
needed.  Unscheduled visits to dispense study medication may be scheduled as needed.  At the Week 12 Visit, the open-label study medication will be dispensed 
and subjects will be instructed not to begin taking rimegepant until confirmation from site staff pending lab results.
6 Subjects must take their study medication every other day, regardless of whether or not they have a migraine.  Subjects must report each tablet they take in the 
eDiary.  Doses are not required to be taken in the office on days of a study visit, however dosing requirements and compliance should be discussed with subjects 
at all visits.  
7 The Observation Period to determine eligibility is 28 days +3 days. The “+3” days window is included for scheduling purposes only.  Subjects with less than 24 
completed eDiary reports during the Observation Period will not be considered for participation due to non-compliance with the eDiary.  Subjects in the Double-
blind, Treatment phase who demonstrate poor compliance will be discussed with the Sponsor and corrective training will be completed by the site with the 
subject.  
8 The electronic subject diary (eDiary) will be dispensed at the Screening Visit, after all Screening Procedures are completed.  The subject will be trained on the 
use of the eDiary.  The subject will use the eDiary every day during the Observation Period and Treatment Phase to report migraine occurrence, migraine severity 
and if the subject treated the migraine.
9 Subjects who do not complete the Double-blind, Treatment Phase or do not enter the Open-label, Extension Phase should complete the End of Treatment Visit 
and 2-Week and 8-Week Follow-up Safety Visits.
10 While on-study, all visit windows are used for scheduling purposes and all efforts should be made to return subjects to the 28-day schedule if scheduling 
changes are made at any previous visit(s).
11 The duration between the Pre-Randomization Lab Visit and the Randomization Visit is 4 days.  The “+2” days window is included for scheduling purposes 
only. Every effort should be made to collect the Pre-Randomization Lab Visit samples as close to, and within, the 4 days prior to the Randomization Visit as 
possible. However, for scheduling convenience, this window may be up to 6 days (between the Pre-Randomization Lab Visit and the Randomization Visit).

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 38 of 91
Table 2.
Schedule of Assessments – Open-label Extension Phase Including End of Treatment (EOT)10 & 
Follow-up Visits
Procedure
Phone visit to 
confirm eligibility 
based on laboratory 
criteria1
Week 14 
(Day 98 ± 3
days)
Week 16 (Day 
112) and 20 
(Day 140)
(±3 days)
Visits every 4 
weeks Week 24
(Day 168) to Week 
64 (Day 448) / 
EOT     (±3 days)
2-Week Follow-
up Safety Visit
(14 days after 
EOT visit ± 2 
days)
8-Week Follow-
up Safety Visit
(8 weeks (-2 
days  to +14 
days) after EOT 
visit)
Confirm Week 12 Laboratory Results
X
Rescue Medication paper diary, 
Concomitant Medication paper diary 
and Menstrual Period paper log 
(female subjects)2
X
X
X
X3
X (Concomitant 
Medication 
paper diary only)
3
Safety Assessments
Physical Examinations
X (Week 16 
only)
X (Week 24 and 64 
/ EOT only)
Vital Signs / Physical Measurements4
X
X
X
Clinical Safety Laboratory Testing
X (Week 16 
only)
X (Week 24, 48, 
and 64 / EOT only)
Liver function tests (LFTs)
X
X
X
X
X
Lipid Panel
X (Week 24 and 64 
/ EOT only)
ECG
X (Week 16 
only)
X (Week 24, 48,
and 64 / EOT only)
X
Urinalysis
X (Week 64 / EOT 
only)
Pregnancy Test
X (urine)
X (urine)
X (urine)
X (serum)

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 39 of 91
Procedure
Phone visit to 
confirm eligibility 
based on laboratory 
criteria1
Week 14 
(Day 98 ± 3
days)
Week 16 (Day 
112) and 20 
(Day 140)
(±3 days)
Visits every 4 
weeks Week 24
(Day 168) to Week 
64 (Day 448) / 
EOT     (±3 days)
2-Week Follow-
up Safety Visit
(14 days after 
EOT visit ± 2 
days)
8-Week Follow-
up Safety Visit
(8 weeks (-2 
days  to +14 
days) after EOT 
visit)
AE, SAE, and Concomitant Procedure
Assessment5
X
X
X
X
X5
Sheehan Suicidality Tracking Scale
X
X
X
X
Clinical Drug Supplies / Study 
Supplies
Dispense Study Medication 1, 6
X
X-all visits except 
Week 64 / EOT
Administer Study Medication7
X
X
X
Enter Use of Study Medication in 
eDiary
X
X
X
Return unused study medication to site 
for compliance check
X
X
X
eDiary returned/reviewed for 
completeness8
X
X
X
Other Assessments
Daily report of migraine occurrence 
and severity reported by subject in 
eDiary9
X
X
X
Migraine-Specific Quality-of-Life 
Questionnaire (MSQ) v 2.1
X (Weeks 24 and
64 only)

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 40 of 91
Procedure
Phone visit to 
confirm eligibility 
based on laboratory 
criteria1
Week 14 
(Day 98 ± 3
days)
Week 16 (Day 
112) and 20 
(Day 140)
(±3 days)
Visits every 4 
weeks Week 24
(Day 168) to Week 
64 (Day 448) / 
EOT     (±3 days)
2-Week Follow-
up Safety Visit
(14 days after 
EOT visit ± 2 
days)
8-Week Follow-
up Safety Visit
(8 weeks (-2 
days  to +14 
days) after EOT 
visit)
Migraine Disability Assessment 
(MIDAS)
X (Weeks 24 and
64 only)
1 Study eligibility must be confirmed by Week 12 laboratory results prior to first dose of study medication, which is dispensed at the Week 12 visit. Sites must 
contact subject by phone to confirm study eligibility prior to subject taking first dose.
2 Concomitant medications, including prophylactic and rescue medications, taken during the Open-label, Extension Phase should be recorded in the subject’s 
paper diary and reviewed by study personnel at each visit. Female subjects will also record menstrual period information on the paper log which should be 
reviewed by study personnel at each visit.
3 Collect if treatment with concomitant medication is required for an AE or if concomitant medication is considered related to AE.
4 Weight, body temperature, respiratory rate, blood pressure, and heart rate will be collected at all timepoints where indicated.  Sitting arterial systolic and 
diastolic blood pressure and radial artery pulse rate will be measured.
5 SAEs, AEs, and Concomitant Procedures must be reported after subject signs informed consent.  SAEs should be reported from signing of consent through the 
8-week Follow up Safety Visit.  Non-serious AEs should be reported from signing of consent through 2-Week Follow up Safety Visit.
6 Subjects should finish a bottle of study medication before starting a new bottle.  Study drug will be dispensed at monthly (every 4 weeks) study visits, as 
needed.  Unscheduled visits to dispense study medication may be scheduled as needed.  Due to the COVID-19 Pandemic, study medication may be shipped to a 
subject, with up to an 8-week supply.  Proper documentation must be maintained in the subject’s source records including shipping vendor, tracking number, 
confirmation of receipt by subject, and all other relevant information.
7 Subjects must take their study medication every other day, regardless of whether or not they have a migraine.  During the open-label, extension phase only, if 
subjects have a migraine on a day that they are not scheduled to take a tablet of study medication, if needed, they may take a study medication tablet to treat a 
migraine on that calendar day.  Therefore, subjects can take a maximum of one (1) tablet of study medication per calendar day.  Subjects must report each tablet 
they take in the eDiary.  Doses are not required to be taken in the office on days of a study visit, however dosing requirements and compliance should be 
discussed with subjects at all visits.  
8 During the Open-Label, Extension Phase, subjects with 6 or more missed evening reports and 3 or more missed dosing entries per month for 2 months 
(sequential or non-sequential months) should be considered for discontinuation from the study for poor compliance, after discussion with Sponsor.  Month is 
defined as 4 weeks for the purpose of this protocol.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 41 of 91
9 The subject will be trained on the use of the eDiary.  The subject will use the eDiary every day during the Extension Phase to report migraine occurrence, 
migraine severity and if the subject treated the migraine.
10 While on-study, all visit windows are used for scheduling purposes and all efforts should be made to return subjects to the 28-day schedule if scheduling 
changes are made at any previous visit(s).  Due to the COVID-19 Pandemic, visits may be conducted remotely (ex: telephone, telemedicine) and must be 
documented within the source records as being conducted remotely.  All procedures not able to be completed due to a visit being conducted remotely must be 
reported as a protocol deviation and can be performed at the next visit, where appropriate to do so based on subject presentation.  In cases where a Week 64 / End 
of Treatment (EOT) visit occurs remotely in order to be completed during the protocol required window and due to the COVID-19 Pandemic, the subject should 
return to the site within the 8 Week Follow-up Safety Visit timeframe (8 weeks from last dose,  -2 to +14 days), to complete all procedures that weren’t able to be 
completed remotely.  Procedures completed at the Week 64 / EOT Remote Visit do not need to be repeated.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 42 of 91
4.3.1
Screening Visit / Observation Period (28 days)
Approximately 1500 subjects will be screened to randomize up to approximately 800 subjects to 
study medication (rimegepant or matching placebo). 
Before any study procedures are performed, subjects must sign informed consent. After informed 
consent, subjects will be enrolled in the IWRS system. The subject’s migraine history and 
medical history will be collected at the Screening Visit.  All subjects will continue to use their 
migraine prophylactic and/or standard of care medications during the 28-day Observation Period.  
Subjects will undergo all screening procedures as detailed in Table 1, after which they will be 
provided an eDiary to document each day during the 28-day Observation Period the occurrence
and severity of migraines. Subjects will also record all migraine standard of care treatments
taken during the Observation Period on a paper diary and female subjects will record their 
menstrual period information on a paper log. After completing the 28-day Observation Period, 
Subjects will return to the clinic, and both their eDiary and paper diary will be reviewed for 
completeness. 
During this period, and within 96 hours +48 hours (4 days +2 days) of the Randomization Visit, 
subjects must return to the study site for the Pre-Randomization Laboratory Visit.  See Table 1
for laboratory tests performed.  Subjects then return to the site for the Randomization Visit; if the 
subject is not eligible, the subject will be considered a Screen Failure.
If the subject meets inclusion/exclusion criteria, the subject may enter the double-blind treatment 
phase. 
4.3.1.1
Pre-Randomization (Laboratory) Visit
Within 96 hours +48 hours (4 days +2 days) of the Randomization Visit, subjects must return to 
the study site for the Pre-Randomization (Laboratory) Visit.  This visit occurs within the 
Observation Period.  Safety labs and a serum pregnancy test for WOCBP will be obtained and 
compliance with the eDiary will be assessed.  If the subject continues to meet study entry criteria 
and laboratory test results are acceptable per protocol, the subject will be randomized at the 
Baseline Visit into the double-blind treatment phase.  If the laboratory results are not acceptable 
per protocol, the subject is determined to be a Screen Failure and must return to the study site to 
return the eDiary. Repeat testing because of liver function test (LFT) abnormalities will not be 
permitted.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 43 of 91
4.3.2
Randomized, Double-blind Treatment Phase (12 weeks)
Once completing the Screening/Observational Period, subjects will return to the study site for the 
Baseline Visit. Subjects who continue to meet all inclusion/exclusion criteria and have been 
compliant with the eDiary may enter the Treatment Phase, pending review of additional 
laboratory test results; see Section 4.3.1.1. Because laboratory results from the Randomization 
(Baseline) Visit will be available after the subject may have been determined to be otherwise 
eligible for the study, had been randomized, and started treatment, there is the possibility that 
exclusionary laboratory results from the Randomization Visit may result in early discontinuation 
from the study.
Subjects will be instructed that they must take one tablet of study drug every other calendar day, 
regardless of whether they have a migraine on that day or not. If subjects have a migraine during 
the double-blind phase of the study, if needed, they may treat the migraine with their standard of 
care medication and continue to take study medication on their regular schedule (scheduled 
dosing days only).
The electronic subject diary will be completed by subjects to capture dosing of study medication 
and the frequency and severity of migraines during the Treatment Phase. 
Subjects will also use the eDiary to complete the Preference of Medication (PoM) and 
Satisfaction with Medication (SM) scales. The Migraine-Specific Quality-of-Life Questionnaire 
v 2.1 (MSQ), the Sheehan Suicidality Tracking Scale (S-STS), Migraine Assessment Disability 
(MIDAS) and Clinical Global Impression (CGI-c) will be completed, or administered by the 
investigator, on paper at specified study visits (Table 1)
Study visits will be approximately every two weeks during the first month and then every 4 
weeks, until Week 12 (Table 1). At each visit, the eDiary will be reviewed by site staff for 
completeness and compliance. Study medication compliance and concomitant medication use 
and menstrual period information (female subjects) will be reviewed (and compared to the 
eDiary and paper diary entries, where applicable) and subjects will be dispensed additional study 
medication as needed. Additional safety (including laboratory tests and ECGs) will be performed 
per the schedule outlined in Table 1. 
4.3.3
Open-label Extension Phase (52 weeks)
It is estimated that approximately 675 subjects will be entered into the open-label extension 
phase.
As indicated in Table 1, laboratory tests will be performed at the Week 12 visit (final visit of the 
double-blind treatment phase of the study).  Subjects who continue to meet all 
inclusion/exclusion criteria and have been compliant with the eDiary may enter the open-label 
extension phase, pending review of laboratory test results.  Subjects will be dispensed study 
medication and will be instructed that they cannot take study medication until laboratory results 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 44 of 91
confirm study eligibility.  Subjects may be contacted by telephone; an office study visit is not 
required.
Subjects will be instructed that they must take one tablet of study drug every other calendar day, 
regardless of whether they have a migraine on that day or not. If subjects in this group have a 
migraine on a day that they are not scheduled to dose with study medication, they may take 1 
study medication tablet on that calendar day to treat a migraine. Therefore, if needed, subjects 
can take a maximum of one tablet of study medication per calendar day for 52 weeks during the 
Open-label, Extension Phase.
The electronic subject diary will be completed by subjects to capture dosing of study medication 
and the frequency and severity of migraines during the Open-label, Extension Phase. 
Subjects will also use the eDiary to complete 
 and 
. The Migraine-Specific Quality-of-Life Questionnaire 
v 2.1 (MSQ), the Sheehan Suicidality Tracking Scale (S-STS), Migraine Assessment Disability 
(MIDAS) and 
 will be completed, or administered by the 
investigator, on paper at specified study visits (Table 2).
Study visits will be approximately every two weeks during the first month and then every 4 
weeks, until Week 64 (Table 2). At each visit, the eDiary will be reviewed by site staff for 
completeness and compliance. Study medication compliance and concomitant medication use 
and menstrual period information (female subjects) will be reviewed (and compared to the 
eDiary and paper diary entries, where applicable) and subjects will be dispensed additional study 
medication as needed. Additional safety (including laboratory tests and ECGs) will be performed 
per the schedule outlined in Table 2. 
Due to the COVID-19 Pandemic, visits may be conducted remotely (ex: telephone, telemedicine) 
and must be documented within the source records as being conducted remotely.  All procedures 
not able to be completed due to a visit being conducted remotely must be reported as a protocol 
deviation and can be performed at the next visit, where appropriate to do so based on subject 
presentation.  
4.3.4
End of Treatment (Week 64) 
Subjects will return to the study at the end of Week 64 (±3 days), or at end of treatment for early 
discontinuations, for review of the electronic diary, assessment of medication compliance, 
assessment of tolerability and safety (including vital signs, laboratory tests,  and  
electrocardiography) (Table 2). In cases where a Week 64 / End of Treatment (EOT) visit occurs
remotely in order to be completed during the protocol required window and due to the COVID-
19 Pandemic, the subject should return to the site within the 8 Week Follow-up Safety Visit 
timeframe (8 weeks from last dose,  -2 to +14 days), to complete all procedures that weren’t able 
to be completed remotely.  Procedures completed at the Week 64 / EOT Remote Visit do not 
need to be repeated.  Subjects must return the unused study medication and electronic subject
diary to the study site. Subjects who do not complete the Double-blind, Treatment Phase and/or 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 45 of 91
do not enter or complete the Open-label, Extension Phase should complete the End of Treatment 
Visit, 2-Week Follow up Safety Visit and 8-Week Follow up Safety Visit.
4.3.5
2-Week Follow up Safety Visit
Subjects will return to the study site 14 days after the Week 64/EOT Visit or early 
discontinuation visit, if applicable, (+/- 2 days) to collect laboratory tests, vital signs, 
electrocardiography, and assessment of AEs/ SAEs. Subjects will return the prophylactic and 
rescue medication paper diary and menstrual period (female subjects) paper logs which should 
be reviewed one final time by study staff.  Subjects must continue to track any concomitant 
medications and therefore must maintain the Concomitant Medication Use Log paper diary
through this visit.  Investigators should assess subjects for AEs consistent with drug dependency 
or withdrawal effects and report as appropriate (see Section 7.4).
4.3.6
8-Week Follow up Safety Visit
Subjects will return to the study site 8 weeks after the Week 64/EOT Visit or early 
discontinuation visit, if applicable (8 weeks (-2 days to +14 days)) to collect liver function tests
(LFTs), assessment of SAEs and to have a serum pregnancy test performed (WOCBP).  Subjects 
will return the Concomitant Medication Use Log paper diary for documenting concomitant 
medications.
4.4
Post Study Access to Therapy (if applicable) 
At the end of the study the sponsor will not continue to supply study drug to subjects or 
investigators. The investigator should ensure that the subject receives appropriate standard of 
care to treat the condition under study.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 46 of 91
5
POPULATION
5.1
Number of Subjects
It is anticipated that up to approximately 1500 subjects may be screened in order to randomize up 
to approximately 800 subjects to study medication (rimegepant or placebo). It is estimated that 
approximately 675 subjects will enter the open-label phase.
5.2
Inclusion Criteria
1. Signed Written Informed Consent
a) Written informed consent must be obtained from the subject in accordance with 
requirements of the study center’s institutional review board (IRB) or ethics committee, 
prior to the initiation of any protocol-required procedures.
b) Subjects must be able to read. 
2. Target Population
Subject has at least 1 year history of migraine (with or without aura) consistent with a 
diagnosis according to the International Classification of Headache Disorders, 3rd Edition2, 
including the following:
a) Age of onset of migraines prior to 50 years of age
b) Migraine attacks, on average, lasting 4 - 72 hours if untreated
c) Per subject report, 4-18 migraine attacks of moderate or severe intensity per month within 
the last 3 months prior to the Screening Visit (month is defined as 4 weeks for the 
purpose of this protocol)
d) 6 or more migraine days during Observation Period
e) Not more than 18 headache days during the Observation Period
f)
Ability to distinguish migraine attacks from tension/cluster headaches
g) Subjects on prophylactic migraine medication are permitted to remain on therapy if the 
dose has been stable for at least 3 months (12 weeks) prior to the Observation Period, and 
the dose is not expected to change during the course of the study.
i. Subjects may remain on one (1) medication with possible migraine-
prophylactic effects, excluding CGRP antagonists [biologic or small-
molecule], during the double-blind treatment phase.  

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 47 of 91
ii. Concomitant use of a CGRP antagonist, such as erenumab or fremanezumab, 
is prohibited.
iii. Subjects who previously discontinued prophylactic migraine medication must 
have done so at least 90 days prior to the Screening Visit.
h) Subjects with contraindications for use of triptans may be included provided they meet all 
other study entry criteria
3. Age and Reproductive Status
a) Male and female subjects ≥ 18 years 
b) Women of childbearing potential (WOCBP) and non-sterile men must be using two 
acceptable methods of contraception to avoid pregnancy throughout the study in such a 
manner that the risk of pregnancy is minimized. See Section 5.6 for the definition of 
WOCBP. Males with vasectomy are considered surgically sterile provided the procedure 
occurred greater than 6 months (24 weeks) prior to study participation.
c) At the Baseline Visit, WOCBP must have a negative pregnancy test (minimum sensitivity 
25 IU/L or equivalent units of HCG) before dosing with study drug
4. Other Inclusion Criteria
a) No clinically significant abnormality identified on the medical or laboratory evaluation. 
A subject with a clinical abnormality or laboratory parameters outside the reference range 
may be included only if the investigator considers the finding not clinically significant, 
that it will not introduce additional risk factors, nor interfere with the study procedures
(not including exclusion criteria listed in Section 5 below)
5.3
Exclusion Criteria
1. Target Disease Exclusion
a) Subject has a history of basilar migraine or hemiplegic migraine
b) Subjects with headaches occurring 19 or more days per month (migraine or non-
migraine) in any of the 3 months prior to the Screening Visit.
2. Medical History and Concurrent Diseases
a) Subject history of HIV disease

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 48 of 91
b) Subject history with current evidence of uncontrolled, unstable or recently diagnosed 
cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and 
cerebral ischemia. Subjects with myocardial infarction (MI), acute coronary syndrome 
(ACS), percutaneous coronary intervention (PCI), cardiac surgery, stroke or transient 
ischemic attack (TIA) during 6 months (24 weeks) prior to screening. 
c) Uncontrolled hypertension or uncontrolled diabetes (however, subjects can be included 
who have stable hypertension and/or diabetes for 3 months (12 weeks) prior to 
screening). Blood pressure greater than 150 mm Hg systolic or 100 mm Hg diastolic after 
10 minutes of rest is exclusionary.
d) Subjects with major depressive episode within the last 12 months, major depressive 
disorder or any anxiety disorder requiring more than 1 medication for each disorder. 
Medications to treat major depressive disorder or an anxiety disorder must have been at a 
stable dose for at least 3 months prior to the Screening visit.    
e) Active chronic pain syndromes (such as fibromyalgia, chronic pelvic pain, complex
regional pain syndrome [CRPS]).
f)
Subjects with other pain syndromes (including trigeminal neuralgia), psychiatric 
conditions, dementia, or significant neurological disorders (other than migraine) that, in 
the Investigator’s opinion, might interfere with study assessments
g) Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, 
Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has a disease that causes 
malabsorption 
h) Subject has a history or diagnosis of Gilbert’s Syndrome or any other active hepatic or 
biliary disorder
i)
The subject has a history or current evidence of any unstable medical conditions (e.g., 
history of congenital heart disease or arrhythmia, known or suspected infection, hepatitis 
B or C, or cancer) that, in the investigator’s opinion, would expose them to undue risk of 
a significant adverse event (AE) or interfere with assessments of safety or efficacy during 
the course of the trial
j)
History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months 
(48 weeks) or subjects who have met DSM-V criteria 9 for any significant substance use 
disorder within the past 12 months (48 weeks) from the date of the screening visit
k) History of use of opioid- or barbiturate- (e.g. butalbital) containing medication for 4 or 
more days per month during the 3 months (12 weeks) prior to Screening Visit. 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 49 of 91
l)
Subjects should be excluded if they have a positive drug screen for drugs of abuse that in 
the investigator’s judgment is medically significant, in that it would impact the safety of 
the subject or the interpretation of the study results. In addition:
i.
Detectable levels of cocaine, amphetamine and phencyclidine (PCP) in the drug 
screen are exclusionary. Subjects who have positive drug screen for 
amphetamines and who are on a prescribed amphetamine medication for an 
approved indication (e.g., ADHD) will be allowed into the study at the 
Investigator’s discretion.  The determination by the Investigator must be well 
documented in the subject’s source medical records.  The stimulant dose must be 
stable from 3 months (12 weeks) prior to baseline until the end of treatment visit 
occurs.
ii.
Detectable levels of marijuana in the drug screen are not exclusionary, if in the 
investigator’s documented opinion the subject does not meet DSM-V  criteria 9
for substance use disorder, and the positive test does not signal a clinical 
condition that would impact the safety of the subject or interpretation of the study 
results.
m) Hematologic or solid malignancy diagnosis within 5 years prior to screening. Subjects 
with a history of localized basal cell or squamous cell skin cancer are eligible for the 
study if they are cancer-free prior to the screening visit in this study.
n) Subject has current diagnosis of major depressive disorder requiring treatment with 
atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder
o) Body mass index > 33.0 kg/m2
p) History of gallstones or cholecystectomy 
3. Allergies and Adverse Drug Reactions
a) History of drug or other allergy which, in the opinion of the investigator, makes the 
subject unsuitable for participation in the study
4. Sex and Reproductive Status
a) WOCBP who are unwilling or unable to use an acceptable contraceptive method or 
abstinence to avoid pregnancy for the entire study period and for up to 8 weeks after last 
dose of study medication
b) Women who are pregnant or breastfeeding. 
c) Women with a positive pregnancy test at screening or prior to study drug administration

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 50 of 91
5. ECG and Laboratory Test Findings
a) Estimated glomerular filtration rate (eGFR) according to the re-expressed abbreviated 
(four-variable) Modification of Diet in Renal Disease (MDRD) Study equation ≤ 40
ml/min/1.73m2
b) Corrected QT interval > 470 msec (QTc by method of Fridericia), at Screening
c) Left Bundle Branch block
d) Right Bundle Branch Block with a QRS duration ≥ 150 msec.
e) Intraventricular Conduction Defect with a QRS duration ≥ 150 msec.
f)
Serum bilirubin (Total, Direct or Indirect) > 1 x ULN (Only abnormal values of between 
1-1.5x ULN may be repeated once for assessment of eligibility during the screening 
period at the Screening Visit only. Abnormal bilirubin results obtained at the Pre-
Randomization Laboratory Visit may not be repeated.)
g) AST or ALT > 1 x ULN (Only abnormal values of between 1-1.5x ULN may be repeated 
once for assessment of eligibility during screening period at the Screening Visit only.
Abnormal AST or ALT results obtained at the Pre-Randomization Laboratory Visit may 
not be repeated.)
h) Neutrophil count ≤ 1000/μL (or equivalent)
i)
HbA1c > 6.5%
6. Prohibited Medications
a) History of use of analgesics (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs] or 
acetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to the 
Screening Visit.
b) Subjects taking a prohibited medication (Refer to Section 5.4). 
7. Other Exclusion Criteria
a) Prisoners or subjects who are involuntarilyincarcerated
b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
(e.g., infectious disease) illness
c) Non-compliance with or inability to complete eDiary during Observation Period. 
Subjects with less than 24 completed eDiary reports during the Observation Period will 
not be considered for participation due to non-compliance with the eDiary.  

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 51 of 91
d) Exposure to non-biological investigational agents (other than rimegepant) within the 30 
days prior to Screening visit.
e) Exposure to biological investigational agents within the 90 days prior to Screening visit. 
f)
Score of > 0 on the Sheehan Suicidality Tracking Scale (See Section 6.2.5) for the period 
of 30 days prior to screening. 
g) Previous enrollment in any multiple dose BHV3000 (rimegepant) study, such as 
BHV3000-201, regardless of the number of doses taken. Subjects may be considered for 
BHV3000-305 if the subject participated in any of the following single dose studies: 
BHV3000-301, BHV3000-302, or BHV3000-303, but did not participate in any multiple 
dose rimegepant study. Note that subjects who were considered screen failures in a past 
BHV3000 study may be considered after discussion with the Sponsor and written 
approval is received.  Subjects who were considered screen failures from BHV3000-305 
may be considered for re-screening provided the ineligibility was due to one of the 
eligibility items adjusted in Amendment 03 (Protocol Version 04): exceeded number of 
headache days (previously greater than 13) or didn’t meet number eDiary entries during 
Observation Period (previously at least 26). Subjects may also be considered for re-
screening provided the ineligibility was due to the eligibility item adjusted in Amendment 
04 (Protocol Version 05): BMI less than 33.0 kg/m2 (previously BMI less than or equal to 
30kg/m2). Subjects who were considered screen failures from BHV3000-305 for other 
reasons should be discussed with the Sponsor and approval must be granted prior to 
considering for re-screening. Adequate documentation in source records must support the 
previously failed criteria.
h) Subjects are excluded if they have had no therapeutic response with > 2 of the 8
medication categories for prophylactic treatment of migraine listed in Appendix 4 after an 
adequate therapeutic trial.  Additional details can be found in Section 15.4 Appendix 4.
i)
Participation in any other investigational clinical trial while participating in this clinical 
trial. Subjects with an exclusionary match found in the CTS Database will be excluded.
j)
Past participation in a clinical trial within 30 days prior to the Screening Visit.  Note: 
Subjects who were considered screen failures within the last 30 days should not be 
considered as excluded.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 52 of 91
5.4
Prohibited Concomitant Medication 
The medications listed below are prohibited starting at the Baseline visit and during the course of 
this study or as specified. 
1. St. John’s Wort should not be taken 14 days prior to the Baseline visit and throughout the 
study.
2. Butterbur root or extracts should not be taken 14 days prior to the Baseline visit and 
throughout the study.
3. History of use of ergotamine medications on > 10 days per month on a regular basis for > 3
months (> 12 weeks)
4. Use of narcotic medication, such as opioids (e.g. morphine, codeine, oxycodone and
hydrocodone) or barbiturates is prohibited starting from 2 days prior to the Baseline Visit and 
throughout the study, including the 8-Week Follow-up Safety Visit. 
5. Use of acetaminophen or acetaminophen containing products for non-migraine indications 
after the Baseline visit is prohibited. Any use of acetaminophen or acetaminophen containing 
products for non-migraine indications during the Observation Period must be stopped at least 
2 days prior to baseline visit. Acetaminophen as a rescue medication as described in 
Section 5.5 is allowed during the Double-blind, Treatment phase. 
6. Use of triptans is prohibited during the Open-label Extension phase. 
7. The use of CGRP antagonists (biologic [e.g. Aimovig™ and Ajovy™] or small molecule) 
other than rimegepant is prohibited during the study.
8. Use of marijuana is prohibited during the study. 
9. Concomitant use of strong CYP3A4 inhibitors with rimegepant is prohibited during the 
double-blind, treatment phase of the study. If use of a strong CYP3A4 inhibitor is required
during the open-label, extension phase, such as use of HIV Protease Inhibitors, Hepatitis C 
protease inhibitors, certain azole antifungals, or clarithromycin, dosing with rimegepant 
should be stopped and should not start again until 14 days after the last dose of the strong 
CYP3A4 inhibitor. Please see Section 15.2 Appendix2.
10. Concomitant use of strong CYP3A4 inducers with rimegepant is prohibited during the 
double-blind, treatment phase of the study. If use of a strong CYP3A4 inducer is required
during the open-label, extension phase, such as use of carbamazepine, phenytoin, or 
rifampin, dosing with rimegepant should be stopped and should not start again until 14 days 
after the last dose of the strong CYP3A4 inducer. Please see Section 15.2 Appendix 2.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 53 of 91
11. Concomitant use of CYP2C9 inhibitors with rimegepant is prohibited during the double-
blind, treatment phase of the study.  If use of a CYP2C9 inhibitor is required during the 
open-label, extension phase, such as fluconazole, amiodarone, or fluvoxamine, dosing with 
rimegepant should be stopped and should not start again until 14 days after the last dose of 
the CYP2C9 inhibitor.  
12. Concomitant use of CYP2C9 inducers with rimegepant is prohibited during the double-blind, 
treatment phase of the study.  If use of a CYP2C9 inducer is required during the open-label, 
extension phase, such as carbamazepine, aprepitant, or rifampin, dosing with rimegepant 
should be stopped and should not start again until 14 days after the last dose of the CYP2C9 
inducer.
13. Concomitant use of atypical antipsychotics such as Abilify (aripiprazole), Zyprexa
(olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), or Risperdal (risperidone) or
Depakote/Depakene (valproic acid/valproate) is prohibited during the study.
14. Concomitant use of LAMICTAL (lamotrigine) is prohibited during the study.
15. Use of analgesics (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen) 
on ≥15 days per month is prohibited during the study
16. Use of any investigational agent other than rimegepant from the Screening Visit through the 
8-Week Follow-up Safety Visit.
5.5
Prophylactic and Rescue Medications
Subjects may not use more than 1 of the following medications with possible migraine-
prophylactic effects if not otherwise prohibited by the protocol.  Doses must be stable within 3 
months (12 weeks) prior to the start of the Observation Period and throughout the study.  
Use of more than 1 of the following medications is prohibited within 3 months (12 weeks) prior 
to the start of the Observation Period and throughout the study.
Prophylactic migraine medications that are permitted during the study include:

Topiramate, gabapentin

Beta blockers (such as: atenolol, bisoprolol, metoprolol, nadolol, nebivolol, pindolol, 
propranolol, timolol)

Tricyclic antidepressants (such as: amitriptyline, nortriptyline, protriptyline)

Venlafaxine, desvenlafaxine, duloxetine, milnacipran

Flunarizine, verapamil, lomerizine

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 54 of 91

Lisinopril, candesartan

Clonidine, guanfacine

Cyprohepatdine

Methysergide

Pizotifen

Feverfew, magnesium (≥ 600 mg/day), riboflavin (≥ 100 mg/day)

Botox®
The use of CGRP antagonists (biologic [e.g. Aimovig™, Ajovy™] or small molecule) other than 
rimegepant is prohibited during the study.
The use of triptan medications is prohibited during the Open-Label, Extension Phase of the 
study, but is allowed as rescue medication during the Double-blind, Treatment Phase.
During the Double-blind, Treatment Phase, subjects may use their permitted standard of care 
medication if needed for acute treatment of a migraine and record any medications taken on the 
appropriate paper diary. Permitted medications include the following rescue medications: 
triptans, aspirin, ibuprofen, baclofen, acetaminophen up to 1000 mg/day for a maximum of 2 
consecutive days at a time (this includes Excedrin Migraine), naprosyn (or any other type of non-
steroidal anti-inflammatory (NSAID)), antiemetics (e.g. metoclopramide or promethazine) or 
muscle relaxants for rescue during the study, with the exception that triptans are prohibited 
during the Open-Label Extension Phase. These are the only medications allowed for rescue. 
Subjects should continue taking study medication on scheduled dosing days.
If a subject takes a tablet of study drug and experiences a migraine later that day, after dosing 
with study drug for the day, the subject may take their rescue medication as described in this 
section of the protocol. During the double-blind, treatment phase, subjects are not allowed to 
take more than one tablet of study medication EVERY OTHER calendar day.  During the 
open-label, extension phase, subjects are required to dose every other day, but may take 1 
tablet of rimegepant on non-scheduled dosing days to treat a migraine.  Subjects are not
allowed to take more than one tablet of study medication per calendar day during the open-
label, extension phase.
Use of standard of care medication during Observation Period and use of rescue medication 
during the Treatment Phase, Extension Phase, and standard of care medication through to the 8-
Week Follow-up Safety Visit will be recorded by the subject on a paper diary and reported to the 
site.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 55 of 91
5.6
Women of Childbearing Potential
Women of childbearing potential (WOCBP) include any female who has experienced menarche 
and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal 
ligation, or bilateral oophorectomy) or is not postmenopausal. Post menopause is defined as:
1. Amenorrhea greater than or equal to 12 consecutive months (48 consecutive weeks) without 
another cause and a documented serum follicle stimulating hormone (FSH) level >
35mIU/mL at screening) or
2. Woman with irregular menstrual periods and a documented serum follicle stimulating 
hormone (FSH) level > 35mIU/mL (at screening) or
3. Woman on hormone replacement therapy (HRT) who no longer menstruate
NOTE: FSH level testing is not required for women greater than or equal to 62 years old with 
amenorrhea of greater than or equal to one year
NOTE: Women on HRT who still menstruate and women with irregular menses should be 
considered as WOCBP
Women of childbearing potential (WOCBP) and men must be using two acceptable methods of 
contraception to avoid pregnancy throughout the study and for up to 56 days after the last dose of 
investigational product in such a manner that risk of pregnancy is minimized. It is required that 
all WOCBP use two methods of contraception for the duration of the study (i.e. beginning at first 
treatment to 56 days after the last dose of study drug). The two methods should include one 
barrier method (ex. condom with spermicidal gel, intrauterine devices, cervical cap etc.) and one 
other method. The other method could include hormonal contraceptives or another barrier 
method.
WOCBP will complete a pregnancy test as outlined in Table 1 and Table 2.  If a WOCBP 
suspects that she might be pregnant, she should immediately contact the study doctor.
5.7
Other Restrictions and Precautions (if applicable)
Not Applicable
5.8
Deviation from Inclusion/Exclusion Criteria and Study Procedures
Any significant event that does not comply with the inclusion / exclusion criteria, study conduct, 
or study procedures will be documented as a deviation. Deviations will be documented and 
reported through the clinical monitoring of the trial. Deviations will be reported to the IRB/EC at 
the frequency required by your IRB/EC. There will be no protocol exceptions granted by the 
Sponsor for Inclusion/Exclusion criteria.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 56 of 91
6
STUDY CONDUCT AND DESCRIPTION OF STUDY PROCEDURES
6.1
Study Materials 
The following study materials will be provided at the study start:

Investigator File/Regulatory Binder

Pharmacy Binder

Drug Accountability Logs

Sample source documents, where applicable

Investigator Brochure

Interactive Web-based Response System (IWRS)

Electronic Case Report Form (eCRF) instructions

Electronic Diary: hand held electronic device (1 will be given to each subject)

Instructions for the eDiary device and access to the portal

Paper diary to record standard of care migraine medications and rescue medications

Paper diary to record menstrual period information (female subjects)

Laboratory Kits and Laboratory Manual

ECG Machine and Instructions

Serious Adverse Event (SAE) forms

Pregnancy Surveillance Forms

Sheehan Suicidality Tracking Scale (S-STS) forms

MIDAS forms

MSQ v 2.1 forms

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 57 of 91
All sites will use an Electronic Data Capture (EDC) tool to submit study data to the CRO.
Electronic Case Report Forms (eCRFs) will be prepared for all data collection fields including
Serious Adverse Events (SAE) Reporting. SAE data (including queries) will be submitted to the 
CRO using eCRFs. 
The eDiary will be used daily to record all study medication dosing, rescue medication dosing
occurrences (i.e., with triptans, ergotamine, or other), select subject-rated scales, and migraine 
occurrence, characteristics, and severity. Any assessment completed by the subject in the eDiary
will be transferred from the site/subject to the vendor and from the vendor to the CRO and 
Sponsor. No additional source documents are required for scales and assessments completed by 
the subject on the eDiary.
Safety laboratory, plasma, and serum instructions for all specimens collected will be provided by 
a designated central laboratory. ECG equipment, supplies, instructions and training materials will 
be supplied by a centralized ECG vendor.
6.2
Safety Assessments
6.2.1
Vital Signs and Physical Measurements (Height and Weight)
Vital signs, body weight and height will be recorded at the scheduled visits as outlined in Table 1
and Table 2.
6.2.2
Electrocardiogram (ECG)
A standard 12-lead ECG will be recorded during the Screening Phase and at all scheduled visits 
as outlined in Table 1 and Table 2. A central ECG service will be utilized for reading all ECGs.  
The over read from the central ECG vendor should be used to determine eligibility for the study. 
The investigator will determine if any ECG abnormalities are clinically significant or not.
6.2.3
Physical Exam
Subjects will undergo a routine physical examination during the Screening Phase and at all 
scheduled visits as outlined in Table 1 and Table 2. Physical examinations to include 
examination of heart, abdomen and lungs, with review of any other system to be guided by 
symptoms.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 58 of 91
6.2.4
Laboratory Assessments
6.2.4.1
Safety Laboratory Testing
Blood and urine samples will be obtained as outlined in Table 1 and Table 2 for clinical 
laboratory evaluations. A central laboratory vendor will be utilized for this study and a 
laboratory manual will be provided to each site. If possible, subjects should be fasting for a 
minimum of 8 hours before laboratory tests. However, if a subject is not fasting at a given 
visit, the blood draw should still be performed, and the non-fasting status should be documented.
1. Clinical safety labs: 
Hematology: Hemoglobin, hematocrit, red blood cell count, white blood cell count with 
differential, and platelets;
Chemistry: Sodium, potassium, chloride, bicarbonate, calcium; glucose, HbA1c, BUN 
(urea), serum creatinine, uric acid, LDH, total protein, albumin, CPK (with local lab 
fractionation, if CK result is > 5.0 x ULN).
eGFR using the estimated MDRD formula (calculated at central lab);
2. LFTs: AST, ALT, Alkaline Phosphatase and Bilirubin (Total, Direct, Indirect).  Additional 
tests may be obtained to evaluate laboratory abnormalities and/or adverse events; please refer 
to the Laboratory manual.
3. Lipid panel: Cholesterol, LDL, HDL, triglycerides
4. Urinalysis: pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, protein, 
glucose, and blood. If blood, protein or leukocytes are positive, reflex to microscopic
examination.
5. Urine Drug Screen: For drugs of abuse
6. FSH: For WOCBP at screening, to determine WOCBP status
Additional tests may be obtained to evaluate laboratory abnormalities and/or adverse 
events; please refer to the Laboratory Manual.
6.2.4.2
Pregnancy Testing
WOCBP will complete pregnancy tests (serum and / or urine) at specified study visits, prior to
taking study medication, and as outlined in Table 1.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 59 of 91
6.2.5
Sheehan Suicidality Tracking Scale  
The Sheehan STS (S-STS) is a prospective, subject-reported or clinician-administered rating 
scale that contains 16 questions to track both treatment-emergent suicidal ideation and 
behaviors.10,11 The S-STS will be completed on a paper form at the site. At the screening visit, 
the recall period for completing the S-STS is 30 days prior; at all other visits, the recall period 
for completing the S-STS is since the last visit. Any responses other than 0 must be immediately 
evaluated by the investigator. If the investigator determines that a subject is at risk of suicide or 
self-harm, appropriate measures to ensure the subject’s safety and obtain mental health 
evaluation must be implemented. In such circumstances, the subject must immediately 
be discontinued from the study. The event should be recorded as either an AE or SAE as 
determined by the investigator and reported within 24 hours to the Sponsor. Any subject with a 
response greater than 0 to any question, excluding Question 2, must be immediately discontinued 
from the study. Subjects with a response of 1 (“a little”) to Question 2 will be discontinued per 
the investigator’s assessment or if the response persists. Subjects with a response greater than 1 
on Question 2 will be discontinued from the study immediately.
6.3
Efficacy Assessments
The eDiary will be used daily to record rescue medication dosing occurrences (i.e., with triptans, 
ergotamine, or other), and migraine occurrence, characteristics, and severity during the 
observation period, double-blind treatment phase, and open-label extension phase.
Efficacy assessments will be derived from eDiary data, and will include the number of migraine 
days by severity (total; moderate or severe) per month, number of  rescue medication days per 
month, and MRM days per month, in each month by study period. 
6.4
Other Assessments
6.4.1
Migraine-Specific Quality-of-Life Questionnaire v 2.1
Impact of treatment on subject-reported quality of life will be assessed using the Migraine-
Specific Qualify-of-Life Questionnaire version 2.1 (MSQ v 2.1). The MSQ v 2.1 is a 14-item 
instrument that has been validated in 3 domains: role function - restrictive, role function -
preventive, and emotional function.12
 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 60 of 91
 
 
 
6.4.4
Migraine Disability Assessment (MIDAS) Questionnaire
The Migraine Disability Assessment (MIDAS) is a retrospective, subject-reported, 5-item 
questionnaire that measures headache-related disability as lost days due to headache from paid 
work or school, household work and non-work activities over a 3-month period. The MIDAS 
will be completed on a paper form at the site.13
 
 
6.5
Early Discontinuation from the Study
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for any of the following reasons:

Withdrawal of informed consent (subject’s decision to withdraw for any reason)

Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study is not in the 
best interest of the subject

Exclusionary laboratory abnormality identified on the Randomization / Baseline Laboratory 
Report.  

Pregnancy

Termination of the study by Biohaven Pharmaceuticals

Loss of ability to freely provide consent through imprisonment or involuntary incarceration 
for treatment of either a psychiatric or physical (e.g., infectious disease) illness

Poor compliance with study procedures and visits, including poor completion compliance 
with evening reports in eDiary. 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 61 of 91
i.
Subjects with less than 24 completed eDiary reports during the Observation Period will 
not be considered for participation due to non-compliance with the eDiary.  
ii.
Subjects in the Double-blind, Treatment Phase will be monitored closely for 
compliance with the eDiary and may not be considered for the Open-label, Extension 
Phase based on PI and / or Sponsor discretion if compliance is low.  Subjects who 
demonstrate poor compliance will be discussed with the Sponsor and corrective 
training will be completed by the site with the subject.
iii.
During the Open-Label, Extension Phase, subjects with 6 or more missed evening 
reports in the eDiary and 3 or more missed dosing entries per month for 2 months 
(sequential or non-sequential months) should be considered for discontinuation from 
the study for poor compliance, after discussion with Sponsor. Month is defined as 4 
weeks for the purpose of this protocol.

Please see Section 6.2.5 for guidance on study discontinuation based on results from the S-
STS.
All subjects who discontinue or who do not enter the Open-label, Extension Phase should 
comply with protocol specified End of Treatment procedures as outlined in Table 2. The only 
exception to this requirement is when a subject withdraws consent for all study procedures or 
loses the ability to consent freely (i.e., is imprisoned or involuntarily incarcerated for the 
treatment of either a psychiatric or physical illness).
 
 
 
 
 
 
 
 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 62 of 91
7
STUDY DRUG MANAGEMENT
7.1
Description of Study Drug
7.1.1
Investigational Product
An investigational product, also known as investigational medicinal product in some regions, is 
defined as follows:
A pharmaceutical form of an active substance or placebo being tested or used as a reference in a 
clinical study, including products already with a marketing authorization but used or assembled 
(formulated or packaged) in a way different from the authorized form, or used for an 
unauthorized indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is 
the responsibility of the investigator to ensure that investigational product is only dispensed to 
study subjects. The investigational product must be dispensed only from official study sites by 
authorized personnel according to local regulations.
In this protocol, investigational product is rimegepant 75 mg tablet or matching placebo. 
7.1.2
Non-investigational Product
Other medications used as support or rescue medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be 
considered as non-investigational products.
In this protocol, non-investigational product(s) is/are: standard of care for acute and preventive 
treatment and rescue medication for migraine treatment.
7.1.3
Packaging, Shipment and Storage
The product storage manager should ensure that the study drug is stored in accordance with the 
environmental conditions (temperature, light, and humidity) as determined by the sponsor. 
Please see the Pharmacy Manual for specific conditions. If concerns regarding the quality or 
appearance of the study drug arise, do not dispense the study drug and contact the sponsor/CRO
immediately.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 63 of 91
7.2
Dose and Administration
7.2.1
Method of Assigning Subject Identification
Immediately after written informed consent is obtained and before performing any study-related 
procedures, the site staff must obtain a subject identification by adding a new subject in Rave. In 
this study, the Rave system will be utilized for obtaining subject identification and as the 
electronic data capture (EDC) system. Each subject will be assigned a unique sequential 4-digit 
subject number through Rave (0001, 0002, 0003, etc.). This subject number must not be reused 
for any other participant in the study. Subjects will maintain their subject number assigned at 
screening throughout the trial. 
At the Baseline Visit, eligible subjects will be randomized in a 1:1 ratio to the rimegepant or placebo 
treatment groups. The randomization will be stratified by the use of prophylactic migraine 
medications (yes or no). 
After confirming subject eligibility, registering a subject for Baseline (Randomization) will 
trigger a container number for the study medication. The study drug will be dispensed at baseline
and as needed at the study visits.
7.2.2
Selection and Timing of Dose and Administration
Study medication (rimegepant or matching placebo) will be assigned via the Rave system. There 
are no dose adjustments in this study and subjects will receive 30 tablets of rimegepant or 
placebo in a bottle. Subjects will be dispensed study medication at the Baseline Visit, and the 
subjects will be instructed that they must take one tablet every other calendar day, regardless of 
whether they have a migraine on that day or not.  This is the scheduled dosing regimen for the 
double-blind treatment phase and the open-label, extension phase.  
During the open-label, extension phase, subjects will receive open-label rimegepant.  Subjects 
will be instructed that they must take one tablet every other calendar day, regardless of whether 
they have a migraine on that day or not.  During the open-label, extension phase only, if a subject
has a migraine on a non-scheduled dosing day, they may take 1 tablet of rimegepant as acute 
treatment for their migraine, if needed, with a maximum of one tablet per calendar day. This 
regimen of scheduled dosing on every other calendar day and as needed rimegepant dosing 
should be followed for up to 52 weeks in the open-label, extension phase. Subjects can take a 
maximum of one tablet of study medication per calendar day for 52 weeks during the open-label, 
extension phase.
Dosing should occur around the same time every other day (EOD) for migraine prevention.  It is 
preferred that subjects dose every other day in the morning, however, it is more important that 
the subject consistently dose at approximately the same time every other day.  The time of 
dosing should be consistent throughout the study for the EOD dosing days.  If the subject has a 
migraine on a day when they already took study medication, the subject can take their rescue 
medication in accordance with protocol restrictions.  Subjects must be instructed that they 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 64 of 91
CANNOT take more than one tablet of study medication every other day during the double-
blind, treatment phase.  Subjects must be instructed to continue taking study medication every 
other calendar day during the open-label, extension phase.  As noted above, subjects may treat a 
migraine with study medication on a non-scheduled dosing day, but subjects must be instructed 
that during the open-label, extension phase, they CANNOT take more than 1 tablet of 
rimegepant per calendar day.  
7.2.3
Dose Modification
There will be no dose adjustments in this study.
7.2.4
Dose Interruptions
If a subject experiences an AE that requires interruption in study medication, the investigator 
should consult with the Sponsor medical monitor to evaluate the need for any additional tests 
prior to re-starting study medication. 
7.3
Blinding and Unblinding 
Blinding is critical to the integrity of this clinical study. However, in the event of a medical 
emergency or pregnancy in an individual subject, in which knowledge of the investigational 
product is critical to the subject’s management, the blind for that subject may be broken by the 
treating physician. 
Before breaking the blind of an individual subject’s treatment, the investigator should have 
determined that the information is necessary, (i.e., that it will alter the subject’s immediate 
management). In many cases, particularly when the emergency is clearly not investigational 
product related, the problem may be properly managed by assuming that the subject is receiving 
active product without the need for unblinding. 
In cases of accidental unblinding, contact the Medical Monitor and ensure every attempt to 
preserve the blind is made.
7.4
Treatment Compliance
Responsible study personnel will dispense the study drug.  Subjects should finish a bottle of 
study medication before starting a new bottle. Accountability and compliance verification should 
be documented in the subject’s study records.  
Subjects must be counseled on the importance of taking the study drug as directed (see 
Section 7.2.2). Treatment compliance, review of study medication doses reported in the eDiary
and through review of returned study medication, should be assessed by site staff at each study 
visit. Discrepancies between doses reported in the eDiary, review of study medication and 
information provided by subject must be documented in the source record. Incorrect or missing 
dosing data and migraine data that are reported in the eDiary will be corrected through either a 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 65 of 91
Data Clarification Record or a Medication Reconciliation Form. Investigators should inform
Subjects that involuntary termination from the study will occur in cases where non-compliance is 
identified. Study staff should contact a subject in between the monthly study visits if the subject
demonstrates non-compliance with the eDiary and document the contact in the source, to identify 
potential lost to follow up subjects as early as possible. 
Investigators must monitor subjects for possible cases of abuse of study medication (subjects
taking study drug for non-therapeutic purposes, e.g. for psychoactive effects such as high or 
euphoria). Investigators should also assess study drug accountability discrepancies (e.g. missing 
study medication, loss of drug, or non-compliance cases in which more study medication was 
used, as compared to expected). Investigators should obtain more information and explanation 
from subjects when there are study drug accountability discrepancies. See Section 8.1.1.
Cases of potential study medication abuse or overdose (including cases of non-compliance with 
study medication dosing instructions or subjects who discontinue treatment without returning 
study medication) should be documented in the source record and reported as an AE or SAE as 
appropriate. Dosing errors (e.g. accidentally taking 2 tablets in one calendar day) should be 
reported as deviations. 
7.5
Destruction and Return of Study Drug
If the study drug (those supplied by the sponsor or sourced by the investigator) are to be 
destroyed on site, it is the investigator’s responsibility to ensure that arrangements have been 
made for the disposal, procedures for proper disposal have been established according to the 
applicable regulations, guidelines and institutional procedures, and appropriate records of the 
disposal have been documented.  The unused study drugs can only be destroyed after being 
inspected and reconciled by the responsible Biohaven (BHV) Study monitor or the sponsor’s 
designee unless this is against institutional policy. 
All unused and/or partially used study drug may be destroyed on site providing the site has an 
applicable standard operating procedure on file.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 66 of 91
8
ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
pre-existing medical condition in a subject or clinical investigation subject administered an 
investigational (medicinal) product and that does not necessarily have a causal relationship with 
this treatment.  An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding for example) symptom, or disease temporally associated with the 
use of the investigational product, whether or not considered relate to the investigational product. 
Adverse events can be spontaneously reported or elicited during an open-ended questioning, 
examination, or evaluation of a subject.  In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.
There are two types of adverse events, Serious Adverse Events (SAE) and Non-Serious Adverse 
Events (AEs).
8.1
SERIOUS ADVERSE EVENT
8.1.1
Definition of Serious Adverse Event (SAE)
An SAE is any event that meets any of the following criteria at any dose:

Death

Life-threatening

Inpatient hospitalization or prolongation of existing hospitalization

Persistent or significant disability/incapacity

Congenital anomaly/birth defect in the offspring of a subject who received rimegepant

Other: Important medical events that may not result in death, be life-threatening, or require 
hospitalization, may be considered an SAE when, based upon appropriate medical judgment, 
they may jeopardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such events are (but not limited to):
o
Intensive treatment in an emergency room or at home for allergic bronchospasm
o
Blood dyscrasias or convulsions that do not result in inpatient hospitalization
o
Development of drug dependency or drug abuse
o
Potential drug induced liver injury (see Section 8.1.5)

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 67 of 91
o
Abuse or Overdose of medication

Potential study medication abuse (including cases of excessive non-compliance with 
study medication dosing instructions or subjects who discontinue treatment without 
returning study medication) should be documented in the source record and reported 
as an AE or SAE as appropriate. Investigators must monitor subjects for possible 
cases of abuse of study medication (subjects taking study drug for non-therapeutic 
purposes, e.g. for psychoactive effects such as high or euphoria). Investigators should 
obtain more information and explanation from subjects when there are study drug 
accountability discrepancies

Potential study medication overdose is defined in Section 8.1.3
Definition of Terms
Mild: Is usually transient and may require only minimal treatment or therapeutic 
intervention. The event does not generally interfere with usual activities of daily living.
Moderate: Is usually alleviated with additional specific therapeutic intervention. The event 
interferes with usual activities of daily living, causing discomfort but poses no significant or 
permanent risk of harm to the subject.
Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may 
require intensive therapeutic intervention.
Life threatening: An AE is life threatening if the subject was at immediate risk of death from the 
event as it occurred; i.e., it does not include a reaction that if it had occurred in a more serious 
form might have caused death. For example, drug induced hepatitis that resolved without 
evidence of hepatic failure would not be considered life threatening even though drug induced 
hepatitis can be fatal.
Hospitalization: AEs requiring hospitalization should be considered SAEs. Hospitalization for 
elective surgery or routine clinical procedures that are not the result of AE (e.g., elective surgery 
for a pre-existing condition that has not worsened) need not be considered AEs or SAEs. If 
anything untoward is reported during the procedure, that occurrence must be reported as an AE, 
either 'serious' or 'non-serious' according to the usual criteria.
In general, hospitalization signifies that the subject has been detained (usually involving at least 
an overnight stay) at the hospital or emergency ward for observation and/or treatment that would 
not have been appropriate in the physician's office or outpatient setting. When in doubt as to 
whether 'hospitalization' occurred or was necessary, the AE should be considered serious.
The following hospitalizations are not considered SAEs in Biohaven clinical studies (but may be 
considered non-serious AEs):

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 68 of 91
1. A visit to the emergency room or other hospital department <24 hours that does not result in 
an admission (unless considered “important medical event” or event that is life threatening);
2. Elective surgery planned prior to signing consent;
3. Admissions as per protocol for a planned medical/surgical procedure;
4. Routine health assessment requiring admission (i.e., routine colonoscopy);
5. Admission encountered for another life circumstance that carries no bearing on health and 
requires no medical intervention (i.e., lack of housing, care-giver respite, family 
circumstances).
Disability/incapacitating: An AE is incapacitating or disabling if the experience results in a
substantial and/or permanent disruption of the subject's ability to carry out normal life functions.
8.1.2
Collection and Reporting Serious Adverse Events
Following the subject’s written consent to participate in the study, all SAEs, whether related or 
not related to study drug, must be collected, including those thought to be associated with 
protocol-specific procedures.   All SAEs must be collected that occur during the observation
phase and up to and including the 8-Week Follow-up. The investigator should report any SAE 
occurring after this time period that is believed to be related to study drug or protocol-specific 
procedures.  
All SAEs should be followed to resolution or stabilization.
An SAE report should be completed for any event where doubt exists regarding its status of 
seriousness.  
If the investigator believes that an SAE is not related to the study drug, but is potentially related 
to the conditions of the study (such as a withdrawal of previous therapy or a complication related 
to study procedure), the relationship should be specified in the narrative section of the SAE 
Report Form. 
SAEs, whether related or not related to study drug, overdose (see Section 8.1.3), potential drug 
induced liver injury (see Section 8.1.5) and pregnancies (see Section 8.1.4) must be reported 
within 24 hours of the Investigator becoming aware of the event. For this study we will be 
capturing SAEs through electronic data capture (EDC) and on the SAE form.
The Investigator is responsible for reporting all SAEs and all Other Important Medical Events to 
 
 
 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 69 of 91
the Investigator, or designated staff, is responsible for entering the SAE information in the 
Electronic Data Capture (EDC) system (i.e.: event term, start stop dates, causality, severity).
Any serious adverse event must be reported immediately or no later than 24 hours after 
awareness of the event to 
 
 
If a form is unable to be submitted within 24 hours, the SAE may be reported by telephone via 
the Safety Hotline Number:
If only limited information is initially available, follow-up reports are required. If an ongoing 
SAE changes in its intensity or relationship to study drug or if new information becomes 
available, a follow-up SAE report should be sent within 24 hours of the Investigator becoming 
aware of the updated information using the same procedure used for the transmission of the 
initial SAE and the same event term should be used.
The minimum information required for an initial SAE report is:
Sender of report (Site number, Investigator name)
Subject identification (subject number)
Protocol number
SAE term (if an SAE is being reported)
8.1.3
Overdose
An overdose is defined as the accidental or intentional administration of any dose of a
product that is considered both excessive and medically important.  
All occurrences of overdose (suspected or confirmed) must be communicated to Biohaven or a 
specified designee within 24 hours and be fully documented as an SAE. Details of any signs or 
symptoms and their management should be recorded including details of any treatments
administered.
Asymptomatic dosing errors (e.g. accidentally taking 2 tablets in one calendar day) should be 
reported as deviations.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 70 of 91
8.1.4
Pregnancy
If, following the baseline visit, it is subsequently discovered that a study subject is pregnant or 
may have been pregnant at the time of the investigational produce exposure, including during at 
least 6 half-lives after the product administration, the investigational product will be permanently 
discontinued in an appropriate manner (i.e., dose tapering if necessary for subject safety).  
Protocol-required procedures for the study discontinued and the follow-up must be performed on 
the subject unless contraindicated by the pregnancy (i.e., x-ray studies).  Other appropriate 
pregnancy follow-up procedures should be considered if indicated.  
The investigator must immediately notify the Biohaven (or designee) Medical Monitor of the 
event and complete the Pregnancy Form within 24 hours and in accordance with SAE reporting 
procedures as described in Section 8.1.2. The pregnancy should be reported using paper forms, 
which should be faxed to 
 
 
 
 
 
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable offspring information must be reported on a Pregnancy Report 
Form.
Any pregnancy that occurs in a female partner of a male study participant should be reported to 
the sponsor.  Information on this pregnancy will be collected on the Pregnancy Report Form, as 
appropriate.   
8.1.5
Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of the initial liver-related laboratory abnormalities 
should occur prior to the reporting of a potential DILI event.  All occurrences of potential DILIs, 
meeting the defined criteria, must be reported as SAEs as per Section 8.1.2. 
Potential drug induced liver injury is defined as: 
1. ALT or AST elevation > 3 times the upper limit of normal (ULN)
AND
2. Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum 
alkaline phosphatase)

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 71 of 91
AND
3. No other immediately apparent possible causes of ALT or AST elevation and 
hyperbilirubinemia, including but not limited to, viral hepatitis, pre-existing chronic or 
acute liver disease, or the administration of other drug(s) known to be hepatotoxic. 
If any potential DILI is identified and meets the criteria above, the Biohaven Medical Monitor 
(or designee) should immediately be contacted for further instruction and whether the subject
must discontinue from the trial and appropriate follow up requirements. 
8.2
Non-serious Adverse Events
A non-serious adverse event is an AE not classified as serious. 
8.2.1
Collection and Reporting of Non-Serious Adverse Events
The collection of non-serious AE information should begin at the initiation of study drug through 
the 2-Week Follow up Safety Visit.    Non-serious AE information should also be collected from 
the start of a placebo lead-in phase or other observation period intended to establish a baseline 
status for a subject. 
Non-serious adverse events should be followed until conclusion or stabilization, or reported as 
SAEs if they become serious.   Follow-up is also required for non-serious AEs that cause 
interruption or discontinuation of study drug or those that are present at the end of study 
treatment. 
8.2.2
Laboratory Test Abnormalities
The following laboratory test abnormalities should be captured on the non-serious AE CRF page 
or SAE Report Form (paper or electronic) as appropriate:
1. Any laboratory test result that is clinically significant or meets the definition of an SAE;
2. Any laboratory abnormality that required the subject to have the study drug discontinued or 
interrupted;
3. Any laboratory abnormality that required the subject to receive specific corrective therapy.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 72 of 91
9
STATISTICS
Complete details on the statistical methods for this study may be found the Statistical Analysis 
Plan (SAP).
9.1
General Procedures
Categorical variables are tabulated with counts and percentages. Continuous variables are 
summarized with univariate statistics (e.g., n, mean, standard error, median, minimum and 
maximum).  
For the calculation of descriptive statistics of observed data, subjects must have a baseline value 
to be evaluable for endpoints based on values and changes from baseline over time.
Tabulations of the following endpoints present the number of unique subjects with an event: 
protocol deviations; interruptions of study therapy; non-study medications; adverse events; and 
laboratory abnormalities. Thus, for these endpoints, multiple occurrences of the same event are 
counted only once per subject.
9.2
Populations for Analysis
The set of enrolled subjects consists of all subjects who signed the informed consent form and 
were assigned a subject identification number.
The set of randomized subjects consists of enrolled subjects who were assigned a randomized 
treatment group and prophylactic migraine medication use stratum.
The full analysis set (FAS) includes all randomized subjects who received at least one dose of 
double-blind study medication (rimegepant or placebo). 
The efficacy analysis set is a subset of the FAS that includes subjects with at least 14 days of 
eDiary data in both the Observation Period and at least one 4-week interval during the double-
blind treatment phase. 
The safety analysis set consists of all enrolled subjects who received at least one dose of study 
medication (double-blind or open-label).   For the double-blind phase, subjects in safety analyses 
will be analyzed based on their randomized treatment so long as they receive at least one dose of 
their randomized treatment. Otherwise, subjects will be analyzed based on the actual treatment 
received.
The rimegepant safety analysis set includes enrolled subjects who received at least one dose of 
rimegepant (double-blind or open-label).

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 73 of 91
9.3
Sample Size
With a sample size of roughly 800 subjects randomized, and 400 subjects per group, we expect 
roughly 370 subjects per group in the efficacy data set.  Assuming rimegepant provides roughly a 
1 day advantage over placebo on the primary endpoint, and a common standard deviation of 3.75 
days, then the study will have roughly 95% power on the primary endpoint.  The estimates for 
the change in migraine days per month and the standard deviation are consistent with publicly 
available information from another investigational oral CGRP antagonist for this indication.
9.4
Primary Endpoint
The change from baseline efficacy endpoint is analyzed using a generalized linear mixed effect 
model, that includes subject as a random effect, and has the baseline number of migraine days  
(i.e., during the Observation Period) as a covariate.  The model includes fixed effects for:
treatment group; stratification factor (use of prophylactic migraine medication); scheduled visit; 
and the visit by-treatment group interaction. Scheduled visits included in the model are 
nominally at 4, 8 and 12 weeks. Evaluation of migraine days per month is based on the data from 
the previous visit to the current visit (i.e., 4-week interval), and is prorated to account for missing 
migraine reports. A migraine days per month endpoint, prorated to 28 days, will be computed for 
subjects in the efficacy analysis set who provide at least 14 days of eDiary data during any 
reporting period (i.e., Observation Period or a 4-week interval during the double-blind treatment 
phase). The difference estimate (rimegepant - placebo), standard error, 95% confidence interval, 
and p-value will be reported for the last 4 weeks (Weeks 9 to 12) of the double-blind treatment 
phase.
9.5
Secondary Endpoint(s)
The number of subjects that experience at least a 50% reduction in the mean number of moderate 
or severe migraine days per month in the last 4 weeks of the double-blind treatment phase will be 
analyzed using a stratified Cochran-Mantel-Haenszel (CMH) test after the missing data are 
imputed as non-response.
The change from baseline in the mean number of migraine days per month over the entire 
double-blind treatment phase (Weeks 1 to 12) will be assessed with the same statistical model 
used to analyze the primary endpoint.
The use of rescue medications (mean number of days per month) in the last 4 weeks of the 
double-blind treatment phase will be assessed using a generalized linear mixed effects model that 
is similar in structure to that used for the primary analysis. Rescue medications are defined in 
Section 5.5.
The change from baseline in the mean number of migraine days per month in the first 4 weeks 
(Weeks 1 to 4) of the double-blind treatment phase will be assessed with the same statistical 
model used for to analyze the primary endpoint.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 74 of 91
The investigators will determine the severity of adverse events (AEs) and the relationship of AEs 
to study therapy. The investigators’ terms will be coded and grouped by system organ class using 
the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) available to the 
analyst. AEs will be presented by system organ class and preferred term. If a subject had an 
adverse event with different severities over time, then only the worst severity will be reported.  
Tabulations will be made for the frequency of unique subjects with adverse events (by severity, 
by relationship to study drug, and overall), serious adverse events, adverse events leading to 
treatment discontinuation, hepatic-related adverse events (by severity, by relationship to study 
drug, and overall), and hepatic-related adverse events leading to treatment discontinuation from 
case report forms. 
The frequency of unique subjects with clinically significant laboratory test abnormalities will be 
tabulated based on Grade 3 - 4 clinical laboratory evaluations graded using the latest version of 
Common Terminology Criteria for Adverse Events (CTCAE). 
Other safety analyses will be described in the statistical analysis plan.
The frequency of unique subjects that have ALT or AST that exceed 3x the ULN concurrently 
(on the same laboratory test occasion) with total bilirubin that exceeds 2x the ULN will be 
tabulated and presented with descriptive statistics and exact confidence intervals. 
Safety endpoints will be assessed separately for the following phases and populations:

Double-blind treatment for the safety analysis set;

Rimegepant treatment (double-blind or open-label) for the rimegepant safety analysis set. 
The changes from baseline in MSQ role function - restrictive domain score and MIDAS total 
score at Week 12 will be analyzed using generalized linear models that include the baseline score 
as a covariate, and fixed effects for treatment group and stratification factor (use of prophylactic 
migraine medication). The Week 12 difference estimate (rimegepant - placebo), standard error, 
95% confidence interval, and p-value will be reported for each endpoint. 
9.6
Multiplicity Correction
Type 1 error is controlled through the use of hierarchical testing.  The significance of the primary 
endpoint is evaluated at the 0.05 level.  If the primary endpoint is significant, then the following 
secondary endpoints will be tested hierarchically in the following order, each at the 0.05 level:

proportion of subjects with a 50% reduction in the mean number of moderate or severe 
migraine days per month in the last 4 weeks of the double-blind treatment phase;

change from baseline in the mean number of migraine days per month over the entire 
course of the double-blind treatment phase; 

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 75 of 91

use of rescue medications (mean number of days per month) in the last 4 weeks of the 
double-blind treatment phase;

change from baseline in the mean number of migraine days per month in the first 4 weeks 
of the double-blind treatment phase;

change from baseline in MSQ role function - restrictive domain scores at Week 12 of the 
double-blind treatment phase;

change from baseline in MIDAS total score at Week 12 of the double-blind treatment 
phase. 
Thus, a secondary endpoint will be tested only if the preceding secondary endpoint in the 
hierarchy is determined to be significant.  Descriptive p-values will be provided for any non-
significant secondary endpoints and comparative exploratory endpoints.
9.7
Demographic and Baseline Characteristics
Tabulations of demographic and baseline characteristics are made for FAS subjects. Separate 
tabulations are made for subjects enrolled but not in FAS.
9.8
Schedule of Analyses
The data from this study may be locked and analyzed at any point after the last subject completes 
their last visit in the double-blind phase of the study, and adequate time has been allowed for 
follow-up.  Analyses of the data may be conducted after the double-blind phase, and at any point
in, or after, the open-label phase.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 76 of 91
10 ETHICS AND RESPONSIBILITIES
10.1
Good Clinical Practice
This study will be conducted in compliance with the protocol, Good Clinical Practice (GCP), 
Good Laboratory Practice (GLP) and all applicable regulations, including the Federal Food, 
Drug and Cosmetic Act, U.S. applicable Code of Federal Regulations (title 21), any Independent 
Ethics Committee (IEC) requirements relative to clinical studies. The study will also be 
conducted in compliance with the recommendations laid down in the most recent version of the 
Declaration of Helsinki, with the exception that registration of such Phase 1 trials in a publicly 
accessible database is not mandatory. 
This study will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.   
All serious breaches must be reported to Biohaven (or designee) immediately.  A Serious breach 
is a breach of the conditions and principles of GCP in connection with the stud or protocol, 
which is likely to affect, to a significant degree, the safety or physical or mental integrity of the 
subjects of the study or the scientific value of the study. 
Study personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective task(s). 
This study will not use the services of study personnel where sanctions have been invoked or 
where there has been scientific misconduct or fraud (e.g., loss of medical licensure, debarment).
10.2
Data and Safety Monitoring Committee
This study will not make use of a Data Safety Monitoring Committee (DMC). The study 
medication rimegepant has been tested and found to be well tolerated.  Safety will be closely 
monitored via oversight by the investigators, Sponsor and CRO/designee and an Institutional 
Review Board/Independent Ethics Committee.
10.3
Informed Consent
Investigators must ensure that subjects, or, in those situations where consent cannot be given by 
subjects, their legally acceptable representatives, are clearly and fully informed about the 
purpose, potential risks, and other critical issues regarding clinical studies in which they 
volunteer to participate. 
Biohaven (or designee) will provide the investigator with an appropriate (i.e., Global or Local) 
sample informed consent form which will include all elements required by ICH, GCP and 
applicable regulatory requirements.  The sample informed consent form will adhere to the ethical 
principles that have their origin in the Declaration of Helsinki.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 77 of 91
Before the potential subject has undergone any study-related screening procedures, the nature of 
the study and the potential risks associated with it will be explained to the subject, and the 
subject will be given an opportunity to ask questions to his or her satisfaction. After the 
questions are answered, but before proceeding further, the subject must read and sign a written 
informed consent form for study participation and CTS database participation. These signed 
informed consent forms will be reviewed and approved by an IRB/IEC, revisions to the protocol 
and informed consent form will be reviewed and approved by the IRB/IEC, a copy retained in 
the Study Master File, and the date and time the subject signed the form will be entered in his or 
her CRF. The subject will be provided with a copy of his or her signed and dated informed 
consent forms.  
If informed consent is initially given by a subject’s legal guardian or legally acceptable 
representative, and the subject subsequently becomes capable of making and communicating 
their informed consent during the study, then the consent must additionally be obtained from the 
subject. 
The informed consent form must also include a statement that Biohaven and its representatives 
and regulatory authorities may have direct access to subject records. 
The Investigators agree to provide the IEC with all appropriate documents, including a copy of 
the protocol/amendments, ICFs, advertising text (if any), Investigator’s brochure and any other 
written information provided to study subjects. The trial will not begin until the Investigators 
have obtained the IEC favorable written approvals for the above-mentioned study documents. A 
properly executed written ICF shall be read, signed, and dated by each subject prior to entering 
the trial or prior to performing any study procedure. The original signed and dated ICF will be 
kept at the Investigator site and a copy will be given to the subject. 
In the event that the protocol is amended, the revised protocol must be approved by the IEC prior 
to its implementation, unless the changes involve only logistical or administrative aspects of the 
trial. If a revised ICF is introduced during the study, each subject’s further consent must be 
obtained. The new version of the ICF must be approved by the IEC, prior to subsequently 
obtaining each subject’s consent. 
The Principal investigator and the Sponsor’s representative must sign the protocol and its 
amendments (if any) before initiating the study. 
It is the Sponsor’s responsibility to submit the protocol and its amendments (if any), and the 
ICFs to regulatory authorities when necessary.
The rights, safety, and well-being of study subjects are the most important considerations and 
should prevail over interests of science and society.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 78 of 91
10.4
Case Report Forms
An Investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation of each study subject. Data 
reported on the CRF that are derived from source documents must be consistent with the source 
documents or the discrepancies must be explained.
Electronic CRFs will be prepared for all data collections fields when electronic data capture 
(EDC) is being used.   
The confidentiality of records that could identify subjects must be protected, respecting the 
privacy and confidentiality rules in accordance with the applicable regulatory requirement(s). 
The Investigator must retain a copy of the CRFs including records of changes and corrections.   
If EDC is being used, signatures will be obtained electronically and a copy of the electronic 
CRFs will be provided (or the data from the CRFs) for future reference.
10.5
Records Management and Retention
In accordance with the principles of GCP and GLP, the study may be inspected by regulatory 
authorities, the Sponsor and CRO. The Sponsor is entitled to access information about the status 
of the study and to review the original documents of the study.
The Investigator must retain all study records and source documents for the maximum required 
by the applicable regulations and guidelines, or institution procedures or for the period of time 
specified by the sponsor, whichever is longer.  The Investigator must contact the Sponsor prior to 
destroying any records associated with this study. 
Biohaven will notify the Investigators when the study files for this study are no longer needed. 
If the Investigator withdraws from the study (i.e., retirement, relocation), the records shall be 
transferred to a mutually agreed upon designee.  Notice of such transfer will be given in writing 
to Biohaven. 
It is the responsibility of the Investigator to ensure that the current disposition record of 
investigational product (those supplied by the sponsor) is maintained at each study site where the 
study drug is inventoried and dispensed.  Records or logs must comply with applicable 
regulations and guidelines and should include:
1. amount of study drug received and placed in storage area
2. label ID number or batch number or Kit number as specified for the protocol
3. amount dispensed to and returned from each subject
4. amount transferred to another area or site for dispensing or storage if applicable

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 79 of 91
5. amount of drug lost or wasted
6. amount destroyed at the site, if applicable
7. amount returned to sponsor, if applicable
8. retain sampled for bioavailability/bioequivalence, if applicable
9. record of dates and initials of personnel responsible for IM dispensing and accountability  
10.6
Source Documentation
An Investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent for all subjects on study.  
If source documents are created to support the collection of study information, this must be 
retained with the other pertinent medical record for each subject for verification of data points.   
Unless otherwise instructed by the Sponsor or designee to enter data directly on the eCRF.
10.7
Study Files and Record Retention
The CRO will maintain adequate study records after completion or termination of study. After 
that period, the Sponsor will be contacted to determine whether the study records will be 
forwarded to the Sponsor, destroyed or kept at CRO or at another facility for a longer period of 
time at the Sponsor's expense.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 80 of 91
11 AMENDMENTS
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Biohaven. A protocol change intended to eliminate an apparent immediate hazard 
to subjects may be implemented immediately, provided the IRB/IEC is notified within 5 days.
Any permanent change to the protocol must be handled as a protocol amendment. The written 
amendment must be submitted to the IRB/IEC and the investigator must await approval before
implementing the changes. Biohaven will submit protocol amendments to the appropriate 
regulatory authorities for approval.
If in the judgment of the IRB/IEC, the investigator, and/or Biohaven, the amendment to the 
protocol substantially changes the study design and/or increases the potential risk to the subject 
and/or has an impact on the subject's involvement as a study participant, the currently approved 
written informed consent form will require similar modification. In such cases, informed consent 
will be renewed for subjects enrolled in the study before continued participation.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 81 of 91
12 STUDY REPORT AND PUBLICATIONS
Biohaven is responsible for preparing and providing the appropriate regulatory authorities with 
clinical study reports according to the applicable regulatory requirements.
The publication policy of Biohaven is discussed in the investigator's Clinical Research 
Agreement.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 82 of 91
13 STUDY DISCONTINUATION 
Both Biohaven and the Principal Investigator reserve the right to terminate the study at the 
investigator’s site at any time. Should this be necessary, Biohaven or a specified designee will 
inform the appropriate regulatory authorities of the termination of the study if needed and the 
reasons for its termination, and the Principal Investigator will inform the IRB/IEC of the same. 
In terminating the study, Biohaven and the Principal Investigator will assure that adequate 
consideration is given to the protection of the subjects’ interests.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 83 of 91
14 CONFIDENTIALITY
All information generated in this study is considered highly confidential and must not be 
disclosed to any person or entity not directly involved with the study unless prior written consent 
is gained from Biohaven. However, authorized regulatory officials, IRB/IEC personnel, 
Biohaven and its authorized representatives are allowed full access to the records.
Identification of subjects and eCRFs shall be by initials and subject numbers only. Only if 
required by law, the subject's full name may be made known to an authorized regulatory agency 
or other authorized official.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 84 of 91
15 APPENDICES
15.1
APPENDIX 1 - Names of Study Personnel

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 85 of 91
15.2
Appendix 2 – Inhibitors and Inducers of CYP3A4 or CYP2C9 (Not all-
inclusive)
The following text presents some of the inhibitors and inducers of CYP3A or CYP2C9. This list 
should not be considered all-inclusive. Individual drug labels should be reviewed for specific 
information on propensity to inhibit or induce CYP450 enzymes for a specific compound. 
As described in the study protocol, concomitant use of strong CYP3A4 inhibitors is prohibited.
Strong CYP3A inhibitors
Boceprevir, cobicistat, conivaptan, danoprevir and ritonavir, elvitegravir and ritonavir, 
indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and 
ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, 
telaprevir, tipranavir and ritonavir, troleandomycin, voriconazole, clarithromycin, 
nefazodone, nelfinavir 
The following medications and supplements are some of the strong inducers of CYP3A4. As 
described in the study protocol, concomitant use of strong CYP3A4 inducers is prohibited. 
Individual product labels should be reviewed for specific information on 
CYP3A inducers
Carbamazepine, phenytoin, rifampin, St. John’s wort
The following medications and medication combinations are some of the inhibitors of CYP2C9. 
As described in the study protocol, concomitant use of CYP2C9 inhibitors is prohibited. 
Individual drug labels should be reviewed for specific information on 
CYP2C9 inhibitors
amiodarone, felbamate, fluconazole, miconazole, piperine, diosmin, disulfiram, fluvastatin, 
fluvoxamine, voriconazole
The following medications and supplements are some of the inducers of CYP2C9. As described 
in the study protocol, concomitant use of CYP2C9 inducers is prohibited. Individual product 
labels should be reviewed for specific information on propensity to 
CYP2C9 inducers
aprepitant, carbamazepine, enzalutamide, rifampin, ritonavir
Resources: 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti
onsLabeling/ucm093664.htm#table3-2
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti
onsLabeling/ucm093664.htm#table3-3

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 86 of 91
Hachad H, Ragueneau-Majlessi I, Levy RH. A useful tool for drug interaction evaluation: the 
University of Washington Metabolism and Transport Drug Interaction Database. Hum 
Genomics. 2010 Oct;5(1):61-72.
University of Washington Metabolism and Transport Drug Interaction Database accessible at 
https://www.druginteractioninfo.org/

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 87 of 91
15.3
Appendix 3 – Definition of Migraine Days
Migraine Day: Any calendar day in which the subject experiences a qualified migraine
headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine 
headache is defined as a migraine with or without aura, lasting for ≥ 30 minutes, and meeting at 
least one of the following criteria (a and/or b)
a) ≥ 2 of the following pain features:

Unilateral location,

Pulsating quality (throbbing),

Moderate or severe pain intensity,

Aggravation by or causing avoidance of routine physical activity (e.g. walking or 
climbing stairs)
b) ≥ 1 of the following associated symptoms:

Nausea and/or vomiting

Photophobia and phonophobia
If the subject took a migraine-specific medication (i.e., study medication [open-label, extension 
phase only], triptan or ergotamine) during aura or to treat headache on a calendar day, then it will 
be counted as a migraine day regardless of the duration and pain features/associated symptoms.
The use of study medication on non-scheduled dosing days is only permitted during the open-
label, extension phase; dosing with study medication on non-scheduled dosing days is not 
permitted during the double-blind, treatment phase.
A moderate to severe migraine day is a migraine day with a migraine reported with moderate or 
severe pain intensity.
Headache Day: Any calendar day in which the subject experiences a qualified headache (initial 
onset, continuation, or recurrence of the headache). A qualified headache is defined as:

a qualified migraine headache (including an aura-only event that is treated with acute 
migraine-specific medication), or

a qualified non-migraine headache, which is a headache that lasts ≥ 30 minutes and is 
not a qualified migraine headache, or

a headache of any duration for which acute headache treatment is administered.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 88 of 91
Acute Migraine-specific Medication Treatment Day: Any calendar day during which the 
subject took a migraine-specific medication (i.e., study medication [open-label, extension phase 
only], triptan or ergotamine). The use of study medication on non-scheduled dosing days is only 
permitted during the open-label, extension phase; dosing with study medication on non-
scheduled dosing days is not permitted during the double-blind, treatment phase.
Monthly eDiary Data: Data collected by the eDiary based on the subject’s monthly
investigational product dosing schedule when at least 14 days of eDiary data are collected within 
that interval. Monthly frequency measurements will be prorated to 28-day equivalents.
Migraine Attack: An episode of any qualified migraine headache. The following rules will be
used to distinguish an attack of long duration from two attacks, or to distinguish between attacks 
and relapses:
a) A migraine attack that is interrupted by sleep, or temporarily remits, and then recurs 
within 48 hours (i.e., ≤ 48 hours between the start of the migraine attack to the time of 
the recurrence) will be considered as one attack and not two.
b) An attack treated successfully with medication but with relapse within 48 hours (i.e., 
≤ 48 hours between the start of the migraine attack to the time of the recurrence) will 
be considered as one attack.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 89 of 91
15.4
Appendix 4 – Categories of Migraine Prevention Medications
No therapeutic response with > 2 of the following 8 medication categories for prophylactic 
treatment of migraine after an adequate therapeutic trial. These medication categories are:
o
Category 1: Divalproex sodium, sodium valproate
o
Category 2: Topiramate, carbamazepine, gabapentin
o
Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, 
nebivolol, pindolol, propranolol, timolol)
o
Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline, 
protriptyline)
o
Category 5: Serotonin-norepinephrine reuptake inhibitors (for example: venlafaxine, 
desvenlafaxine, duloxetine, milnacipran)
o
Category 6: Flunarizine, verapamil
o
Category 7: Lisinopril, candesartan
o
Category 8: Botox®
No therapeutic response is defined as no reduction in headache frequency, duration, or severity 
after administration of the medication for at least 6 weeks at the generally-accepted therapeutic 
dose(s) based on the investigator’s assessment.
The following scenarios do not constitute lack of therapeutic response:
o
Lack of sustained response to a medication
o
Failure to tolerate a therapeutic dose

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 90 of 91
16 REFERENCES
1.
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the 
acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. 
Cephalalgia. 2014;34(2):114-125.
2.
Headache Classification Committee of the International Headache Society (IHS) The 
International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3.
CN170003. A Phase 2b, adaptive, double-blind, randomized, multi-center outpatient, 
dose-ranging trial to evaluate the efficacy and safety of BHV-92771 for the acute treatment of 
moderate or severe migraine.
4.
CN170002. Effect of BMS-927711 on the Pharmacokinetics of a Combined Oral 
Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects.
Bristol-Myers Squibb Company;2012.
5.
CN170004. Phase 1 open-label, randomized single sequence study with two dose groups 
to compare the pharmacokinetics of BMS-927711 in migraine subjects during an acute migraine 
attack and during nonmigraine period. Bristol-Myers Squibb Company;2012.
6.
CN170006. Phase 1 Mass Balance Recovery Study - Rimegepant oral dosing and 
infusion. Bristol-Myers Squibb Company
7.
CN170007. DDI with Midazolam (CYP3A4 substrate) to study the changes of 
midazoloam pharmacokinetics with or without BMS-92771. Bristol-Myers Squibb Company.
8.
Hougaard A, Tfelt-Hansen P. Review of dose-response curves for acute antimigraine 
drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert opinion on drug metabolism & 
toxicology. 2015;11(9):1409-1418.
9.
APA. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 5th 
Edition. 5th ed: American Psychiatric Publishing; 2013.
10.
Sheehan DV, Alphs LD, Mao L, et al. Comparative Validation of the S-STS, the ISST-
Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality 
Categories. Innovations in clinical neuroscience. 2014;11(9-10):32-46.
11.
Sheehan DV, Giddens JM, Sheehan IS. Status Update on the Sheehan-Suicidality 
Tracking Scale (S-STS) 2014. Innovations in clinical neuroscience. 2014;11(9-10):93-140.
12.
Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-
specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204-215.

Protocol BHV3000-305 
Confidential
Randomized, Double-blind, Placebo-controlled Study for Migraine Prevention
Version 9
Page 91 of 91
13.
Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument 
assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. 
Headache. 2001;41(9):854-861.
14.
Guy W. ECDEU Assessment Manual for psychopharmacology. In: Rockville, Md. : U.S. 
Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and 
Mental Health Administration, National Institute of Mental Health, Psychopharmacology 
Research Branch, Division of Extramural Research Programs; 1976.